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INTRODUCTION 
 In 1943, Haagensen and Stout  identified “grave clinical signs” 
predicting poor outcome in women with primary breast cancer treated with 
radical mastectomy. These features include the presence of extensive skin 
edema, satellite nodules, intercostal or parasternal nodules, arm edema, 
supraclavicular metastasis, inflammatory carcinoma, or distant metastasis, or 
the presence of two or more of the following: ulceration of the skin, skin 
edema of limited extent (more than one-third of the breast), fixation to the 
chest wall, axillary lymph nodes larger than 2.5 cm, or fixation of axillary 
lymph nodes to the skin or deep structures of the skin. Other clinical signs of 
locally advanced disease included a single tumor larger than 10 cm in size, 
multiple tumors in one breast, redness of the skin, and skin involvement.  
This classical description of the clinical contraindications to the primary 
surgical management of primary breast cancer is, in general, still valid 
today. In Haagensen's series of patients with these grave signs, local 
recurrence rates were 42% despite radical mastectomy, and no patient 
survived disease-free for 5 years. Patients with these characteristics (and 
having no distant metastases) are currently included in the category of 
locally advanced breast cancer (LABC). The poor outcome of these patients 
when treated with radical mastectomy led to the investigation of other 
treatment strategies. 
The definition of LABC has evolved from that of Haagensen and Stout, to 
encompass a 
 wide spectrum of clinical presentations: 
• Large tumors (>5 cm) 
• Extensive regional lymph node involvement 
• Direct involvement of the underlying chest wall or skin with edema 
(including peau d'orange) or ulceration or satellite skin nodules 
confined to the same breast. Other discrete skin changes, such as 
dimpling or nipple retraction, may occur in T1-3 disease; they do not 
constitute evidence of a locally advanced tumor. 
• Tumors considered inoperable but without distant metastasis 
(including involvement of the supraclavicular lymph nodes) 
• Inflammatory breast cancer (IBC) 
Acording to the AJCC staging,LABC comprises of :  
T3 Tumor more than 5 cm in greatest dimension  
T4 Tumor of any size with direct extension to a. Chest wall or b. Skin 
T4a Extension to chest wall, not including pectoralis muscle  
T4b Edema (including peau d’orange) or ulceration of the skin of the breast, 
or satellite skin nodules confined to the same breast 
T4c Both T4a and T4b  
T4d Inflammatory carcinoma  
Regional Lymph Nodes (N) 
NX Regional lymph nodes cannot be assessed (e.g., previously removed) 
N0 No regional lymph node metastasis 
N1 Metastasis in movable ipsilateral axillary lymph node(s) 
N2 Metastases in ipsilateral axillary lymph nodes fixed or matted, or in 
clinically apparent(1) ipsilateral internal mammary nodes in the absence of 
clinically evident axillary lymph node metastasis 
N2a Metastasis in ipsilateral axillary lymph nodes fixed to one another 
(matted) or to other structures  
N2b Metastasis only in clinically apparent(1) ipsilateral internal mammary 
nodes and in the absence of clinically evident axillary lymph node 
metastasis 
N3 Metastasis in ipsilateral infraclavicular lymph node(s) with or without 
axillary lymph node involvement, or in clinically apparent(1) ipsilateral 
internal mammary lymph node(s) and in the presence of clinically evident 
axillary lymph node metastasis; or metastasis in ipsilateral supraclavicular 
lymph node(s) with or without axillary or internal mammary lymph node 
involvement 
N3a Metastasis in ipsilateral infraclavicular lymph node(s)  
N3b Metastasis in ipsilateral internal mammary lymph node(s) and axillary 
lymph node(s)  
N3c Metastasis in ipsilateral supraclavicular lymph node(s)  
 T4 is defined as a tumor of any size  
with direct extension to chest wall, not including pectoralis muscle. 
 
 A. T4b, illustrated here as satellite skin nodules, is defined as edema 
(including peau d’orange) or ulceration of the skin of the breast, or satellite 
skin nodules confined to the same breast. B. T4b illustrated here as edema 
(including peau d’orange). 
 
 
 
 T4c is defined as both T4a and T4b.                   T4d, inflammatory carcinoma. 
   
Table 1 Stage grouping of LABC 
 
Stage  Tumor 
size 
Node Metastasis  
 T3 N0 M0 
IIIA T0 N1 M0 
 T1(7) N2 M2 
 T2 N2 M2 
 T3 N1 M0 
 T3 N2 M0 
III B T4 N0 M0 
 T4 N2 M0 
 T4 N2 M0 
III C Any T N3 M0 
IV  Any T Any N M1 
 
Note: Stage designation may be changed if post-surgical imaging studies 
reveal the  resence of distant metastases, provided that the studies are carried 
out within 4 months of diagnosis in the absence of disease progression and 
provided that the patient has not received neoadjuvant therapy. 
 All T and N permutations included in stage IIB, III or IV comprised 
many distinct substage possibilities. The presence of T4 or N3 or regional M1 
lesions would result in inclusion in the stage IIIB/IV unresectable 
subcategory. Most of the patients with either T3 or N2, but without T4, N3 or 
regional M1 lesions, are included in the stage II/IIIA or operable 
subcategory. LABC also includes T2 tumors that are too large in proportion 
to the size of the breast.In the most recent TNM staging system, tumours 
associated with ipsilateral supraclavicular nodal basin have been eliminated 
from the LABC category because the supraclavicular nodal basin lies 
outside the primary lymphatic drainage pathways of axilla and internal 
mammary nodes;tumours associated with supraclavicular nodes have been 
reclassified as stage IV disease.However as the patients with distant 
metastases confined to the supraclavicular  nodes have a better prognosis 
than patients with metastases at other sites and can be rendered disease free 
with locoregional therapy,metastases limited to the ipsilateral sub-
supraclavicular fossa have been included in the category of LABC defined 
here. 
 LABC is a heterogeneous group of tumors of varying clinical 
presentations and biological behavior whose only common bonds are the 
presence of a large primary tumor, or  extensive regional lymph node 
involvement, and the absence of any evidence of distant metastases. Some 
patients have a rapid neoplastic evolution, whereas others present with a long 
history of tumor growth. 
 The clinical diagnosis of LABC is usually not difficult. Patients 
uniformly present with a large breast mass. Other symptoms often reported 
are edema, redness, nipple retraction, pain, skin dimpling, an axillary mass 
and breast ulceration. Most physical findings are obvious upon inspection or 
palpation. However, in younger women, some tumors infiltrate the breast 
diffusely and a discrete mass is difficult to palpate. More than 75% of 
patients have clinically palpable axillary and/or supraclavicular adenopathy, 
and 65%-90% of patients have pathologically confirmed lymph node 
metastasis; >50% have more than four nodes involved. Most of the LABCs 
are operable; only 25%-30% are diagnosed at an inoperable stage. 
 A physical examination, bilateral mammogram and ultrasound of the 
breast and its draining lymphatics determine the extent of involvement 
within the breast and the nodal chains, the presence of additional tumor foci 
within the same breast or the contralateral breast, and the extension of the 
tumor to deeper structures.  
 A core needle biopsy is quite effective in establishing the diagnosis 
and also allowing tumor samples to be obtained for hormone receptors, DNA 
studies and other biomarkers. The sensitivity and specificity of fine-needle 
aspiration are quite high in LABC. The only disadvantages of cytological 
diagnosis are the inability to differentiate between in situ and invasive 
carcinoma, and scant material on which to perform additional studies. 
Excisional biopsies are not indicated in patients with LABC. 
 Appropriate staging procedures should be performed in patients with 
LABC since the probability of distant metastases is high. Approximately 
20% of these patients, appropriately staged, have detectable distant 
metastases at the time of diagnosis.So after a complete history, a physical 
examination should be performed with great attention to the evaluation of 
both breasts and all surrounding lymph node-bearing areas. All tumors 
 
  
 
 
 
Table 2 Diagnosis and pathology 
Level of 
resources 
Clinical Pathology Imaging and 
laboratory tests 
Basic  History  
 
Physical  examination  
Clinical berate examination 
Surgical blopey  
Fine – needle aspiration blopey  
Interpretation of 
biopeies  
Cytology of pethology 
report decribing tumor 
size  
Lymph node status  
Hietologic type, tumor 
grade 
 
 
Limited  Core needle biopey  
Image guided sampling  
(ultraaonographic + 
mammographic)  
Determination and 
reporting of ER and 
PR status  
Diagnostic breat 
ultrasound + 
diagnodetic 
mammography 
Plain cheet 
radiography  
Enhanced  Preoperative needle 
localization under 
memographic of ultra sound 
guidance  
On-site 
cytopethologist  
Liver ultrasound 
Blood chemiatry 
profile / CBC  
Diagnostic 
mammography 
bone scan  
Maximal Stereotaatic biopey  
Sentinel node biopey  
HER- 2 neu statue  
IHC staining if 
sentinel nodes for 
sytokertin to detect 
micrometaataaee  
CT scanning . PET 
acan MIBI scan , 
breat MRI  
 should be described by the longest perpendicular diameters in cm, and 
the presence of palpable axillary, supraclavicular and subclavicular nodes, 
with exact measurements of their longest perpendicular diameters, should be 
included. A close-up photograph is useful in the staging of patients with T4 
tumors. Ideally, the initial evaluation should be done simultaneously by the 
medical oncologist, surgical oncologist and radiotherapist.  
Table 3 NCCN – Guide lines for LABC 
LOCALLY ADVANCED INVASIVE BREAST CANCER  
 
CLINICAL STAGE    WORKUP  
 
Stage III A 
T0, N2 , M0 
T1, N2 , M0     H&P 
T2, N2 , M0     CBC Platelets 
T3, N2 , M0     Liver function tests 
( Stage III A patients with T3  Chest imaging   
N 1 M0 disease , see BiNV-1   Pathology review  
      Prechemotheraphy determination of 
Stage III B     tumor ER/ PR receptor status and HER2  
T4, N0 , M0     status  
T4, N1 , M0     Diagnostic bilateral mammogram,  
T4, N2 , M0     ultrasound as necessary 
      Bone scan ( catergory2B)  
Stage III C     Abdominal CT or US or MRI  
Any T, N3,M0    category 2B)  
      Breast MRI (optional)  
 
 
 After the physical examination and bilateral mammogram, the 
following additional tests are recommended: a biochemical profile, including 
tests of liver and renal function, and calcium level; chest x-ray; bone scans; 
radiographs of areas that appear to be abnormal on the bone scan; computed 
tomography of the liver and an ultrasonography of the breast and regional 
lymph nodes to precisely assess the tumor extent. The importance of an 
accurate initial assessment of the extent of primary tumor burden cannot be 
overemphasized since the efficacy of subsequent local treatment will depend 
mostly on this initial assessment.  
 Patients with LABC are at great risk for morbid local complications of 
their disease, including skin breakdown, tissue necrosis, bleeding, pain, and 
infection. These problems, which may not alter survival, significantly 
compromise quality of life. Patients with locally advanced breast cancer also 
have a very high rate of systemic micrometastasis at diagnosis, which if 
untreated will progress and lead to organ dysfunction and death. There are 
thus two central goals in the treatment of LABC:  
♦ Obtaining and maintaining local control with surgery and/or 
radiotherapy,  
♦ Improving overall survival by control of systemic disease with 
chemotherapy and/or hormonal therapy. 
Arriving at a uniform treatment plan for LABC is limited by the biologic 
diversity of the disease (there are 13 possible combinations in the current 
TNM staging system  for stage III breast cancer ranging from minute tumors 
with bulky axillary disease to large tumors with microscopic axillary 
disease). 
Historical perspective & Review of literature.: 
 During the last 60 years, the management of LABC has evolved 
considerably. Initially, patients with LABC were treated with radical 
mastectomy.Based on the disappointing results of surgery and radiotherapy 
in patients with LABC, and the early promising results of adjuvant systemic 
therapy in women with axillary node-positive breast cancer, systemic 
therapy was subsequently incorporated along with surgery and radiotherapy 
into the management of patients with LABC, termed “combined modality 
therapy.” Even with such combined modality therapy, the long-term survival 
rate is approximately 50% among patients with LABC.  
 
 Surgery and LABC : 
 For many years, the Halsted radical mastectomy was the standard 
treatment for breast cancer.The pioneering work of McWhirter et al in the 
mid 20th century showed that less mutilating surgery produced results equal 
to that of radical mastectomy.The failure of halstedian principle of en-bloc 
extirpation of the breast and draining lymph nodes to cure many patients of 
breast cancer,frequent identification of small breast cancer by 
mammography,and success of moderate doses of  radiotherapy in 
eliminating sub clinical foci of  breast cancer led to the development of  
MRM .MRM is a term used to describe a variety of surgical procedures,but 
all involve complete removal of the breast and some of the axillar nodes. 
Table 4 summarizes the results of surgery alone in the treatment of LABC; 
these studies were retrospective and did not follow uniform staging 
classifications. Some included stage T1 patients in addition to LABC, and 
some patients were treated with radiation therapy and chemotherapy. These 
studies confirmed that surgery alone was inadequate treatment Even with 
aggressive surgical techniques,patients with advanced local disease had a 
high incidence of localregional recurrence. Most important, surgery did not 
change the pattern of distant failure in patients who probably had 
micrometastatic disease 
The advent of radiation therapy in LABC  
 The use of radiation therapy alone in the treatment of locally 
advanced noninflammatory breast cancer was no more effective than surgery 
alone (Table 5). The local recurrence rates of 36% to 72% were even higher 
than those reported for surgery alone. This difference in local-regional 
failures was no longer evident when patients were treated with a 
combination of radiation therapy and surgery, which suggested that the two 
treatment modalities might provide better results if used together. The 
patients’ high rate of distant relapse, however, emphasized the need for 
systemic therapy as well. 
TABLE 4 SURGERY ALONE IN THE TREATMENT OF LABC 
Author Institution No of 
patients  
5 year local 
Recurrence 
Rate (%)  
5 year 
survival 
(%)  
10 year 
DFS  (%) 
Haagensan 
and stout  
Columbia- 
Presbyterian  
35 45.7 5.7 - 
Schottenfield 
et al  
MSKCC 62 6 53 29 
Arnold and 
Lesnick  
Mount sinai 
hospital  
50 50 33 22 
Fracchia et 
al 
MSKCC 207 25 43 27.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5 RADIATION ALONE IN THE TREATMENT OF LOCALLY 
ADVANCED BREAST CANCER 
 
AUTHOUR YEAR INSTITUTION NO OF 
PATIENTS
5-YR LOCAL 
RECURRENCE 
RATE % 
DISEASE 
FREE 
SURVIVAL%
Zucali et al 1976 Instituto 
Nazionale 
Tumori 
321 49 21 
Rubens et 
al 
1977 Guy’s hospital 184 72 18 
 
 
Bruckman 
et al 
1979 Joint centre for 
Radiation 
therapy 
116 36 22 
Rao et al 1982 Malinckrodt 
Institue of 
Radiology 
54 51 16-20 
Harris et al 1983 Joint centre for 
Radiation 
therapy 
137 46 28 
 
Combined Surgery and Radiation Therapy 
 
 In early attempts to improve locoregional control in treating patients 
for LABC, radiation therapy was combined with surgical therapy. Although 
these studies showed promising results in locoregional control, they failed to 
address the systemic nature of LABC, and patients still died of metastatic 
disease. The lessons learned in those years emphasized the need for 
additional treatment modalities. First, even though combined radiation and 
surgical therapy delayed the time to first local-regional relapse, there was no 
significant survival advantage. Second, preoperative radiation therapy was 
often able to convert an inoperable breast cancer to an operable one. Third, 
preoperative radiation therapy did not seem to differ from postoperative 
radiation in providing additional locoregional control. Last, a combination of 
surgery and radiation therapy provided the maximum chance for 
locoregional control over high-dose radiation therapy or surgery alone. 
Table 6 summarizes selected series in which combination surgery and 
radiation therapy were used pre or postoperatively to treat LABC patients. 
The results showed that even combining radiation therapy and surgery did 
not eliminate locoregional failures. 
 
MULTIMODAL THERAPY 
 
Haagensen and Stout's early paper on the criteria of operability in carcinoma 
of the breast made clear that the vast majority of patients with locally 
advanced disease would develop distant metastatic disease. This has been 
confirmed in multiple trials of surgery and radiation therapy alone or in 
combination.Multimodality  therapy that included surgery, radiation therapy, 
chemotherapy, and hormonal therapy has had the greatest impact on 
survival.   
 
 
 
 
 
TABLE 6 : COMBIMATION SURGERY AND RADIATION THERAPY IN THE 
TREATMENT OF LOCALLY ADVANCED BREAST CANCER 
 
AUTHOUR YEAR INSTITUTION NO OF 
PATIENTS
5-YR LOCAL 
RECURRENCE 
RATE % 
DISEASE 
FREE 
SURVIVAL%
 
(Pre-
op)Cade 
1949 Westminster 
Hospital 
95 - 10 
Zucali et al 1976 Instituto 
Nazionale 
Tumori 
133 - 45 
Whitaker 
& 
Battersby 
1977 Princess 
Alexandra 
Hospital 
68 77.9 - 
(Post-
op)Arnold 
& Lesnick 
1979 Mount Sinai 
Hospital 
54 70 32 
Townsend 
et al 
1984 University of 
Texas 
53 11 10-35 
Arnold & 
Lesnick 
1979 Mount Sinai 
Hospital 
122 70 30 
Bedwinek 
et al 
1982 Malinckrodt 
Institue of 
Radiology 
93 12-13 - 
Montague 
& Fletcher 
1985 M.D Andersn 
Cancer Centre 
132 13 43.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
. TABLE 7 : SUMMARY OF STUDIES WITH SURGERY FOLLOWED BY 
ADJUVANT  CHEMOTHERAPY 
 
 
 
 
 
Study Patients No 
of 
Pts 
Treatment 
Regimens 
Duratio
n of 
Follow-
Up 
Level Of 
Evidence 
Results/Recommendations 
Kletsform 
et al 
1987 
Stage III 
breast 
cancer 
patients 
after 
MRM 
120 1.Radiotherap
y 
2.VAC 
3.Both 
5 yr I DFS better with combned 
treatment 
trhan with either radiotherapy 
alone 
 or VAC alone 
Derman 
et al 
LABC 231 1.Radiotherap
y 
2.Radiotherap
y + low dose 
CMF 
3.Radiotherap
y + high dose 
CMF 
56 
months 
II No difference in DFS /OS 
between 
 the three groups 
De 
Placido  
et al 
Stage II / 
III breast 
cancer 
after 
mastectom
y 
220 1.CMF 
chemotherapy 
alternating 
with EV 
2. CMF 
chemotherapy 
48 mo II No difference in DFS /OS 
between 
 the two groups 
Casper  
et al 
LABC 
treated by 
MRM / 
RM 
41 6 mo CAF + 6 
mo CMFVP 
24 mo II Median DFS 23 months in CAF + 
CMFVP group,15 months in  
CMFVP alone;Median OS 33  
Months in CAF + CMFVP , 
18 months in CMFVP alone 
Olson  
et al 
LABC 
who 
underwent 
Mastectom
y & 
treated 
with 
CAFTH 
313 1.Radiotherap
y 
2.Observation 
+ RT if 
locoregional 
failure 
9.1 year II DFS not reported.Median survival 
 8.3 year in RT group; 
locoregional recuurance 15% in 
RT , 24% in observation group  
 
 
 
 
 
 Multidisciplinary approach to LABC : 
 
 The clinical management of LABC is complex and should be tailored 
to the individual patient. Frequently, surgery, radiotherapy and systemic 
therapy (chemotherapy, hormone therapy) are used. A multidisciplinary 
approach to LABC is recommended in which treatment is based on the 
combined opinions of a surgeon, radiation oncologist and medical 
oncologist. The initial management of LABC requires histological 
confirmation (e.g., core biopsy, incisional biopsy or skin biopsy) for 
diagnosis and for determination of hormone receptor and HER-2 neu 
oncogene status. Cytological evaluation by fine-needle aspiration is 
insufficient. 
                   
LABC
Treatment pathways
Clinically stage IIIA, IIIB, & IIIC Breast cancer
WORK UP
Operable 
Stage IIIA 
Inoperable Stage IIIA & 
stage IIIB
Neoadjuvant therapy(3-4 cycles)
Response No response
Operable Inoperable 
Individualised
therapySurgery 
               
     
Systemic therapy: chemotherapy 
 
Operable tumours • Patients with operable stage IIIA disease should be 
offered  
 
chemotherapy. They should receive adjuvant chemotherapy following 
surgery, or  
 
primary chemotherapy followed by locoregional management.  
 
Patients with stage IIIA breast cancer have potentially operable tumours. 
There are 2 approaches for treating these patients. The first is modified 
radical mastectomy (MRM) followed by adjuvant systemic therapy and 
radiotherapy, and the second is preoperative chemotherapy followed by 
surgery and adjuvant chemoradiation. 
. 
LABC - Management protocol
Operable LABC
Desires breast 
conservation
Does not desire breast 
conservation
Pre operative 
chemotherapy
No response after 3-
4 cycles or 
progressive disease
Partial response 
– lumpectomy 
not possible
Complete response 
or partial response 
with lumpectomy 
possible
Lumpectomy with adjuvant 
chemotherapy, radiotherapy & 
hormone therapy
Mastectomy with adjuvant 
chemotherapy, radiotherapy    
& hormone therapy  
Choice of chemotherapy 
 
• Chemotherapy should contain an anthracycline. Acceptable regimens 
are 6 cycles of FAC, CAF, CEF or FEC. Taxanes are under intense 
investigation 
 Randomized trials have confirmed the superiority of anthracycline-
containing regimens such as  CEF and CAF over conventional CMF in 
women with node-negative and node-positive breast cancer. In contrast, in 
the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-15 
trial, 4 cycles of AC chemotherapy was equivalent to 6 months of CMF. 
Although there are limitations to crossstudy comparisons, it is reasonable to 
consider that 4 cycles of AC, although equivalent to 6 months of CMF, is 
probably inferior to 6 cycles of anthracycline-containing drug regimens such 
as FAC, CAF, CEF and FEC. In women who cannot receive anthracyclines 
because of underlying cardiac disease, CMF chemotherapy can be 
considered. 
 Six cycles of chemotherapy should be administered. This is based on 
the trials of adjuvant chemotherapy that showed that 6 cycles of CAF or 
CEF was superior to 6 cycles of CMF and that 6 cycles of FEC were 
superior to 3 cycles of FEC.  
NON-TRASTUZUMAB CONTAINING REGIMENS (all category 1) 
 
FAC/CAF (fluorouracil/doxorubicin/cyclophosphamide)  
FEC/CEF (cyclophosphamide/epirubicin/fluorouracil) 
AC (doxorubicin/cyclophosphamide) ± sequential paclitaxel 
EC (epirubicin/cyclophosphamide) 
TAC (docetaxel/doxorubicin/cyclophosphamide) 
A CMF (doxorubicin followed by 
cyclophosphamide/methotrexate/fluorouracil) 
E CMF (epirubicin followed by 
cyclophosphamide/methotrexate/fluorouracil) 
CMF (cyclophosphamide/methotrexate/fluorouracil) 
AC x 4 (doxorubicin/cyclophosphamide) + sequential paclitaxel x 4,every 2 
weekly regimen with filgrastim support 
A T C (doxorubicin followed by paclitaxel followed by cyclophosphamide) 
every 2 weekly regimen with filgrastim support 
FEC T (fluorouracil/epirubicin/cyclophosphamide followed by docetaxel) 
 
Neoadjuvant Therapy 
 The use of neoadjuvant or induction chemotherapy was first reported 
in the 1970s . Perez  and colleagues reported their results of a pilot study by 
the Southeastern Cancer Study Group in 1979. This small study included 14 
patients (five patients had inflammatory breast cancer and five had 
recurrences after mastectomy). All patients were treated with 5-flurouracil, 
Adriamycin (doxorubicin), and cyclophosphamide (FAC) for two courses, 
followed by local therapy or radiation concurrently with cyclophosphamide 
and 5-fluorouracil (CF). In the Perez group’s study, all patients received an 
additional eight courses of FAC. All but three of the patients had complete 
regression of their tumors following radiation therapy. The primary tumor 
showed partial regression (50% to 75%) in 65% of the patients after the first 
two courses of FAC.However all the trials concluded that induction 
chemotherapy was feasible but did not show any significant survival benefit 
. 
Given the absence of any difference in outcome for patients treated with 
neoadjuvant versus adjuvant chemotherapy, the decision to use preoperative 
versus postoperative chemotherapy must be based on other factors. Factors 
in favor of preoperative chemotherapy include the following:  
(1) patients initially presenting with tumors that historically required 
mastectomy can potentially be down-staged to allow for breast-conservation 
treatment; 
 (2) larger tumors that require a cosmetically unsatisfactory lumpectomy at 
presentation can be down-staged to allow a more cosmetically favorable 
lumpectomy;  
 (3) the response of individual patients to systemic chemotherapy can be 
assessed in vivo; 
 (4) research can be facilitated, for example, by evaluating tissue specimens 
before and after treatment, to rapidly assess new chemotherapeutic, 
hormonal, or biologic agents; & 
(5) the pathologic response to neoadjuvant chemotherapy is a strong 
prognostic factor for outcome. 
 The argument in favor of primary surgery, if possible, with adjuvant 
systemic therapy is the more accurate pathologic staging, both of the 
primary tumor as well as the axillary lymph nodes, with the valuable 
prognostic information acquired for prognosis and guidance of adjuvant 
therapy. 
 Numerous studies have demonstrated high rates of down-staging to 
breast-conservation treatment with the use of neoadjuvant chemotherapy. 
Although most studies have used doxorubicin- or epirubicin-containing 
regimens, studies have also begun to evaluate the role of taxane 
chemotherapy. After neoadjuvant chemotherapy, down-staging of the tumor 
sufficient to allow breast-conservation treatment has been reported in 22% to 
90% of patients. For those patients with sufficient down-staging to permit 
breast-conservation surgery, definitive breast irradiation is also indicated and 
is delivered in a manner similar to that for patients not treated with 
neoadjuvant chemotherapy.  
 Because physical examination and mammography do not adequately 
predict the pathologic response to neoadjuvant chemotherapy, alternative 
imaging methods have been developed to attempt to more accurately predict 
a pathologic response and to improve breast-conservation rates. MRI is one 
promising modality  and appears to correlate well with pathologic response. 
 Hormone therapy likely has a role to play as a neoadjuvant therapy, 
particularly when the diagnostic biopsy results confirm hormone receptor 
expression. The addition of endocrine therapy to chemotherapy appears to 
improve outcome for patients with locally advanced breast cancerThe role of 
postmastectomy radiation treatment after neoadjuvant chemotherapy is in 
evolution. The ASCO guidelines recommend that, in general, 
postmastectomy radiation treatment is indicated after neoadjuvant systemic 
therapy, although the guidelines recognize that there may be exceptions to 
this recommendation. The rationale for recommending postmastectomy 
radiation treatment is the significant down-staging associated with 
neoadjuvant chemotherapy, for both the primary tumor and axillary lymph 
nodes, and the fact that most patients who require mastectomy have 
presented initially with locally advanced tumors (T3 or T4 lesions) or four or 
more pathologically positive axillary lymph nodes. For postmastectomy 
radiation treatment after neoadjuvant chemotherapy followed by 
mastectomy, unresolved issues at this time include which patient and tumor 
factors (clinical and pathologic) should be used to select those patients who 
require treatment and the optimal technical radiation therapy fields, 
including which regional lymph nodes, if any, should be treated. 
Breast Conservation in the Setting of Multimodal Therapy 
 
 The concept of breast conservation in patients with LABC was 
initially practiced to spare patients surgery who already had an extremely 
poor prognosis. Initial studies with radiation therapy alone accomplished 
breast conservation, but at the expense of a high rate of local-regional failure 
and distant relapse. Even studies of multimodal therapy in which only 
radiation was used as local therapy have had local-regional failure rates as 
high as 30% to 50%. The ability to reduce local failures by combining 
surgery and radiation therapy makes breast conservation treatment more 
appealing. Because induction chemotherapy may result in significant 
reductions in the size of the primary tumor, 
many patients with LABC would be candidates for breast conservation with 
a combination of surgery and radiation therapy. 
 In 1990, Bonadonna et al” first reported the use of induction 
chemotherapy to downstage primary tumors and allow subsequent breast 
saving surgery. The criterion for breast-saving surgery was a reduction in the 
tumor size to less than 3 cm. The group was able to avoid mastectomy for 
127 (81%) of the 157 patients who had a surgical procedure.The treatment 
regimen consisted of three to four cycles of chemotherapy (CMF, FAC, or 
FEC [5-fluorouracil, epirubicin, cyclophosphamide]),followed by surgery 
and postoperative radiation therapy. Only116 women received postoperative 
adjuvant chemotherapy. Complete responses were seen after chemotherapy 
in 27 women, although histopathologic CR occurred in only nine. Up to 60% 
of the patients had at least a partial response to the induction chemotherapy. 
Among the first 83 patients who underwent surgery with at least 12 months 
of followup, 
the disease recurred in 13. Only one of the 75 women treated with breast 
conservation surgery experienced a local recurrence during this period. One 
patient treated with mastectomy had a local recurrence, and the remaining 11 
patients developed distant metastases. 
Targeted therapy – recent advances  
 Advances in molecular biology are reaching therapeutic application 
on several fronts. One example is the targeting of the HER-2 tyrosine kinase 
receptor. Trastuzumab (Herceptin, Genentech, San Francisco) is a 
humanized monoclonal antibody that binds to HER-2 with great affinity, 
resulting in growth arrest of HER-2 overexpressing cancer cells. The 
addition of trastuzumab to AC and paclitaxel improves time to progression, 
response rates, and overall survival for patients with advanced breast cancer 
overexpressing HER-2. Monoclonal antibodies are large molecules and are 
likely to be more effective in the adjuvant setting. Randomized trials that 
integrate trastuzumab in combination with chemotherapy are under way. 
Table  8 BREAST CONSERVATION AFTER MULTIMODALITY 
TREATMENT IN LABC 
 
Inoperable tumours 
 
• Patients with stage IIIB or IIIC disease, including those with 
inflammatory breast cancer and those with isolated ipsilateral internal 
mammary or supraclavicular lymph-node involvement, should be 
treated with primary anthracycline-based chemotherapy. • Acceptable 
chemotherapy regimens are FAC, CAF, CEF or FEC. Taxanes are 
under intense investigation. 
Inoperable LABC
Preoperative chemotherapy
Response No response
Total mastectomy 
with surgical 
axillary staging
RT to chest wall and 
supraclavicular LNs
and internal mammary 
nodes if involved +/-
delayed breast 
reconstruction
Lumpectomy with 
axillary staging 
RT to breast, 
supraclavicular
LNs & internal 
mammary if 
involved
Consider 
additional 
chemotherapy 
+/- pre op RT
response No 
response
As above individualise
Additional chemotherapy + hormone therapy 
if ER+/unknown  
 
NON-TRASTUZUMAB COMBINATIONS 
FAC chemotherapy : 
5-Fluorouracil 500 mg/m IV days 1 & 8 or days 1 & 4 
Doxorubicin 50 mg/m IV day 1 (or by 72 h continuous infusion) 
Cyclophosphamide 500 mg/m IV day 1 Cycled every 21 days for 6 cycles. 
CAF chemotherapy 
Cyclophosphamide 100 mg/m PO days 1-14 
Doxorubicin 30 mg/m IV days 1 & 8 
5-Fluorouracil 500 mg/m IV days 1 & 8 Cycled every 28 days for 6 cycles. 
AC chemotherapy 
Doxorubicin 60 mg/m IV day 1 
Cyclophosphamide 600 mg/m IV day 1 
Cycled every 21 days for 4 cycles. 
FEC chemotherapy 
Cyclophosphamide 75 mg/m PO days 1-14 
Epirubicin 60 mg/m IV days 1 & 8 
5-Fluorouracil 500 mg/m IV days 1 & 8  
With cotrimoxazole support.Cycled every 28 days for 6 cycles. 
AC followed by paclitaxel chemotherapy 
Doxorubicin 60 mg/m IV day 1 
Cyclophosphamide 600 mg/m IV day 1 Cycled every 21 days for 4 
cycles.Followed by 
Paclitaxel 175-225 mg/m by 3 h IV infusion day 1 Cycled every 21 days for 
4 cycles. OR 
Paclitaxel 80 mg/m by 1 h IV infusion weekly for 12 weeks. 
EC chemotherapy 
Epirubicin 100 mg/m IV day 1 
Cyclophosphamide 830 mg/m IV day 1 Cycled every 21 days for 8 cycles. 
TAC chemotherapy 
Docetaxel 75 mg/m IV day 1 
Doxorubicin 50 mg/m IV day 1 
Cyclophosphamide 500 mg/m IV day 1 Cycled every 21 days for 6 cycles. 
(All cycles are with filgrastim support). 
A followed by CMF chemotherapy 
Doxorubicin 75 mg/m IV day 1 Cycled every 21 days for 4 cycles. 
Followed by Cyclophosphamide 600 mg/m IV day 1 
Methotrexate 40 mg/m IV day 1 
5-Fluorouracil 600 mg/m IV day 1 Cycled every 21 days for 8 cycles. 
E followed by CMF chemotherapy 
Epirubicin 100 mg/m IV day 1 Cycled every 21 days for 4 cycles. 
Followed by Cyclophosphamide 100 mg/m PO days 1-14 
Methotrexate 40 mg/m IV days 1 & 8 
5-Fluorouracil 600 mg/m IV days 1 & 8 Cycled every 28 days for 4 
cycles.OR 
Cyclophosphamide 750 mg/m IV day 1 
Methotrexate 50 mg/m IV day 1 
5-Fluorouracil 600 mg/m IV day 1 Cycled every 21 days for 4 cycles. 
CMF chemotherapy 
Cyclophosphamide 100 mg/m PO days 1-14 
Methotrexate 40 mg/m IV days 1 & 8 
5-Fluorouracil 600 mg/m IV days 1 & 8 Cycled every 28 days for 6 cycles. 
Dose-dense AC followed by paclitaxel chemotherapy 
Doxorubicin 60 mg/m IV day 1 
Cyclophosphamide 600 mg/m IV day 1 Cycled every 14 days for 4 cycles. 
Followed by Paclitaxel 175 mg/m by 3 h IV infusion day 1 Cycled every 14 
days for 4 cycles.(All cycles are with filgrastim support). 
Dose-dense A-T-C chemotherapy 
Doxorubicin 60 mg/m IV day 1 Cycled every 14 days for 4 cycles. 
Followed by Paclitaxel 175 mg/m by 3 h IV day 1 Cycled every 14 days for 
4 cycles. 
Followed by Cyclophosphamide 600 mg/m IV day 1 Cycled every 14 days 
for 4 cycles. 
(All cycles are with filgrastim support). 
FEC followed by docetaxel chemotherapy 
5-Fluorouracil 500 mg/m IV day 1 
Epirubicin 100 mg/m IV day 1 
Cyclophosphamide 500 mg/m day 1 Cycled every 21 days for 3 cycles. 
Followed by Docetaxel 100 mg/m day 1 Cycled every 21 days for 3 cycles. 
TRASTUZUMAB CONTAINING COMBINATIONS 
AC followed by T chemotherapy with Trastuzumab 
Doxorubicin 60 mg/m IV day 1 
Cyclophosphamide 600 mg/m IV day 1 Cycled every 21 days for 4 cycles. 
Followed by Paclitaxel 175 mg/m by 3 h IV day 1 Cycled every 21 days for 
4 cycles OR 
Paclitaxel 80 mg/m by 1 h IV weekly for 12 wks With Trastuzumab 4 mg/kg 
IV with first dose of paclitaxel Followed by Trastuzumab 2 mg/kg IV 
weekly to complete 1 year of treatment. As an alternative, trastuzumab 6 
mg/kg IV every 3 wk may be used following the completion of paclitaxel, 
and given to complete 1year of trastuzumab treatment. 
Cardiac monitoring at baseline, 3, 6, and 9 months. 
 
Docetaxel + trastuzumab followed by FEC 
Docetaxel 100 mg/m by 1 h IV day 1 Cycled every 21 days for 3 cycles 
With 
Trastuzumab 4 mg/kg IV with first dose of docetaxel day 1 Followed by 
Trastuzumab 2 mg/kg IV weekly to complete 9 weeks of 
trastuzumab.Followed by 
5-Fluorouracil 600 mg/m IV day 1 
Epirubicin 60 mg/m day 1 
Cyclophosphamide 600 mg/m day 1 Cycled every 21 days for 3 cycles 
Cardiac monitoring at baseline, after last FEC cycle, at 12 and 36 months 
after chemotherapy. 
TCH (docetaxel, carboplatin, trastuzumab) 
Docetaxel 75 mg/m IV day 1 Followed by 
Carboplatin AUC 6 IV day 1 Cycled every 21 days for 6 cycles With 
Trastuzumab 4 mg/kg week 1 Followed by 
Trastuzumab 2 mg/kg for 17 weeks Followed by 
Trastuzumab 6 mg/kg IV every 3 weeks to complete 1 year of trastuzumab 
therapy 
Cardiac monitoring at baseline, 3, 6, and 9 months. 
 
AC followed by docetaxel with trastuzumab 
Doxorubicin 60 mg/m IV day 1 
Cyclophosphamide 600 mg/m day 1 Cycled every 21 days for 4 cycles 
Followed by 
Docetaxel 100 mg/m Cycled every 21 days for 4 cycles With 
Trastuzumab 4 mg/kg IV week one Followed by 
Trastuzumab 2 mg/kg IV weekly for 11 weeks Followed by 
Trastuzumab 6 mg/kg every 21 days to complete 1 y of trastuzumab therapy 
Cardiac monitoring at baseline, 3, 6, and 9 months. 
Neoadjuvant T followed by FEC chemotherapy with trastuzumab 
Trastuzumab 4 mg/kg IV for one dose beginning just prior to first dose of 
paclitaxel 
Followed by 
Trastuzumab 2 mg/kg IV weekly for 23 wks 
Paclitaxel 225 mg/m by 24 h IV infusion every 21 days for 4 cycles 
Followed by 
5-Fluorouracil 500 mg/m on days 1 and 4 
Epirubicin 75 mg/m IV on day 1 
Cyclophosphamide 500 mg/m on day 1 Cycled every 21 days for 4 cycles 
Systemic therapy: hormonal therapy 
 
Operable and inoperable tumours 
 
• Tamoxifen for 5 years should be recommended to pre-and 
postmenopausal women whose tumours are hormone responsive. 
Schinzinger was the first person to propose that oophorectomy might be 
of benefit in breast cancer based on the following observations : 
• Post menopausal breast atrophies. 
• More virulent tumor growth in premenopausal  women. 
The first reported series of surgical oophorectomy for breast cancer was 
reported by Thomas Beatson (1896).The report postulated the following 
effects of oopherectomy 
• Significant tumor regression by castration 
• Better sense of well being 
• Regression of cutaneous metastasis 
• Best above age of 40  
• No effect on osseous metastatsis 
Following Beatson's original report, oophorectomy became widely practiced 
but then was largely abandoned after only 10 years. The reasons why the 
procedure was abandoned are (a) the recognition that oophorectomy was not 
a curative procedure, as was originally thought by Beatson;  
(b) the lack of a sound therapeutic rationale; and 
 (c) the risks of intraabdominal surgery in the early twentieth century. 
It was not until the 1940s, when Charles Huggins described the hormonal 
responsiveness of prostatic cancer, that an interest in the hormonal treatment 
of breast cancer was resurrected . 
  The various modalities of endocrine manipulation available in the 
management of advanced breast cancer include : 
 Selective Estrogen Receptor Modulators: 1.Tamoxifen 
                                                                  2.Torimefen  
Androgens : Fluoxymesterone 
Progestins : Megestrol acetate 
   Medroxyprogesterone acetate 
High dose Estrogens 
 Aromatase inhibitors:1st generation: Aminoglutethemide 
                    2nd generation: Formestane (Type I) , Fadrazole 
  3rd generation: Exemestane (Type I) , Anastrazole ,                          
Letrozole,  Vorozole 
Steroidal Antiestrogens: Fulvestrant 
LHRH agonists : Leuprolide,   Goserelin 
Gland ablation : surgical (open/laparoscopic) ; chemical ;  radiation 
• Ovary ;  Pituitary ; Adrenals 
 
SELECTIVE ESTROGEN RECEPTOR MODULATORS : 
The SERMs are chemically diverse compounds that lack the steroid 
structure of estrogens but possess a tertiary structure that allows them to 
bind to the estrogen receptor. 
Examples:  Tamoxifen ; Raloxifen ; Tormifen 
The Selective modulation explained by: 
o Differential estrogen-receptor expression in a given target tissue 
o Differential estrogen-receptor conformation on ligand binding  
o Differential expression and binding to the estrogen receptor of 
coregulator proteins 
Tamoxifen 
Chemically a triphenylethylene.the trans isomer of which is used as a citrate 
salt. 
Mechanism Of Action: Competitive binding to the estrogen receptor 
resulting in reduction of transcription of estrogen regulated genes. 
Dimethylaminoethoxy side chain and the trans configuration are crucial 
for the antiestrogenic activity of tamoxifen 
The net result is a block in the G1 phase of the cell cycle and a slowing of 
cell proliferation.Tamoxifen is thus, a cytostatic drug. 
Binding and inactivation of estrogen receptor in cancerous cell : 
Predominant mode of action 
Other postulated mechanisms: 
Initiation of apoptosis in malignant cells 
Reduction of serum IGF-1 and increase in IGF-1 binding proteins are 
another potential mechanism of action. 
Other actions: 
Increased sex hormone binding globulin ( ? Reduced estrogen 
bioavailability) 
Increased TGF β ( ? Increased pulm fibrosis / breast fibrosis if used 
concurrently with RT) 
Selective activation / inactivation of corepessors and coactivators 
responsible for selective agonist / antagonist activity 
Ancillary benefits of Tamoxifen 
 
 
Cardiovascular: 
Fewer non cancer related deaths due to cardiovascular events. 
Fewer hospitalizations for cardiac events 
Serum LDL / cholesterol reduced. 
Skeletal: 
Significant reduction in incidence of fractures of weight bearing bones. 
Estrogen agonist action on BMD 
Prevention of contralateral breast cancer 
Toxicity 
Menopausal symptoms:50% - 60% ( N.B. 40% - 50% in placebo) 
          MC in premenopausal 
           Vaginal dryness and discharge may occur in excess. 
Depression: 
Maybe seen in as high as 10% of patients. 
But no randomized comparisons available. 
Ocular toxicity: 
Keratopathy 
Thromboembolism:Severe thromboembolism seen in ~ 1% patients in the 
preventive setting.The risk is up to 10 times that experienced by healthy 
women.This complication is more common in elderly patients with 
metastatic breast cancer and who are receiving CCT 
Carcinogenesis:There is increased risk of endometrial cancers (hazard rate of 
1.7 per 1000 – NSABP B 14 data)but mostly low grade & stage I tumors. 
Other tumors: Hepatomas & Clear cell sarcomas of ovary 
Contraindications to Tamoxifen Treatment : 
Absolute: Retinal macular edema or degeneration 
History of benign or malignant liver tumor secondary to oral contraceptives 
Pregnancy 
Other hormonal therapy (estrogens, oral contraceptives) 
Relative: History of thrombophlebitis, particularly hormone related 
History of depression, particularly hormone related 
Cataract 
Drugs: Chlorpromazine, chloroquine, thioridazine, amiodarone, other 
Severe vasomotor symptoms 
Polycystic ovaries 
 
 
Radiation oophorectomy 
The first series on the effectiveness of radiation oopherectomy was reported 
by Foveau de Courmelles in 1922.The considerations in advocating 
Radiation oophorectomy include:1.  Non invasive and cheap procedure. 
             2.Low dose carries little additional morbidity. 
             3.However takes about 2 – 3 months for effect to appear. 
             4.For such reason best avoided when prompt relief is needed. 
             5.Also best reserved for the patient with slow progression of disease. 
Technique:   Position: Supine 
Field selection: Parallel opposing two field technique 
Energy : Co60 or 6 MV LINAC 
Dose Schedules:  
In a younger women 10 – 12 Gy in 5 -6 divided fractions is preferred. 
In older women shorter course of radiation can give equivalent ovarian 
ablation. 
Field borders: 
The volume of interest is the entire true pelvis 
10 x 15 cm field is opened. 
Lower border is placed just below the superior border of pubic symphysis. 
Recommendations for adjuvant hormonal therapy :                         
Following completion of chemotherapy, pre- or postmenopausal patients 
with LABC and hormone-responsive tumours should receive adjuvant 
tamoxifen therapy, 20 mg/d, for 5 years  Tamoxifen should be started after 
completion of chemotherapy. The aromatase inhibitor, anastrozole, has been 
compared with tamoxifen in postmenopausal women with early breast 
cancer following surgery. The early results of that study showed that , 
compared with tamoxifen, anastrozole was associated with improved DFS 
and had fewer side effects. The role of aromatase inhibitors as adjuvant 
therapy in breast cancer is evolving. The role of luteinizing hormone-
releasing hormone agonists in premenopausal patients is evolving as new 
data emerge . Patients who are not candidates for any chemotherapy can be 
managed with hormonal treatment and then receive locoregional 
management. 
  
 
 
 
NCCN GUIDELINES FOR HORMONAL  THERAPY : 
 
 
 
Locoregional management 
 
Operable tumours 
 
• Patients with stage IIIA disease should receive both modified radical 
mastectomy (MRM) and locoregional radiotherapy if feasible. They 
may be managed with MRM followed by chemotherapy and 
locoregional radiotherapy, or chemotherapy first followed by MRM and 
locoregional radiotherapy. Breast-conserving surgery is currently not a 
standard approach.  
MRM (mastectomy plus a level 1 and level 2 axillary dissection) remains the 
standard surgical treatment for operable locally advanced disease. The 
second half of the 20th century witnessed increasing disillusionment with 
radical and mutilating forms of surgery for breast cancer. As a result the 
trend towards breast conservation has increased since the mid-1960s, 
although a number of centres had adopted this approach since before the 
Second World War. Again there are a number of different descriptions 
relating to breast conservation which has caused confusion. Tumourectomy, 
lumpectomy, tylectomy, segmental mastectomy, and quadrantectomy are all 
synonymous with a therapeutic procedure in which the primary tumour is 
removed and the breast is preserved. Unfortunately, these terms are not 
precisely defined, although they imply the removal of varying amounts of 
normal breast tissue in association with a primary tumour. The terms 
&lsquo;lumpectomy&rsquo, &lsquo;tumourectomy&rsquo and 
lsquo&tylectomy&rsquo; imply removal of the tumour with a minimal or no 
margin of normal breast tissue around it. Segmental mastectomy implies 
excision of the tumour with a rim of associated normal breast tissue. 
However, this term is also somewhat misleading as it implies that the breast 
is anatomically a segmental organ and that tumours occur in a localized 
segment. This is clearly not the case. The term 
lsquo;quadrantectomy&rsquo; denotes removal of a breast quadrant, and 
implies wider excision of normal breast tissue than segmental mastectomy. 
In practice, however, there is little distinction between these terms and 
although a number of authorities have recommended the adoption of a 
uniform nomenclature, none has found universal favour. 
 Once the questions regarding definition of terms and nomenclature 
have been addressed the simple, yet fundamentally important question which 
remains is whether breast conservation provides results as reliable in the 
treatment of breast cancer as total  Mastectomy. Furthermore, is there an 
additional benefit in terms of cosmetic and emotional adjustment? Finally, if 
breast conservation is justified, in which patients is this appropriate?  
 The role of BCS is unclear and the subject of research. Previous 
studies demonstrating equivalence of BCS to mastectomy were performed in 
patients with stage I and II disease  see guideline  In the trials that compared 
preoperative chemotherapy with chemotherapy administered 
postoperatively, the proportion of women with tumours greater than 5 cm in 
diameter ranged from 5% to 27%. Patients with operable stage III disease 
who desire to preserve their breast should be made aware that BCS is 
currently not a standard approach and is generally not recommended. 
TABLE 9 THERAPY OVERVIEW : MRM VS BCT 
Therapy Strengths 
 
Weaknesses Required resources  
MRM Effective local 
treatment  
Uses surgical 
technique widely  
available   
Short post treatment 
convealeacence  
Limited long term 
complications 
RT can be avoided 
in some cases  
 
Loss of body image 
(mutilations)  
Negative 
psychosocial impact  
RT is often still 
necessary  
 
 
Core surgical 
resources  
Trained surgeon  
General anesthesia   
Operating room  
Post operative care 
facility  
Pathology  
Post mastectomy 
irradiation of the 
chest wall regional 
lymphnodes  
 
 
BCT Equivalent survival 
to MRM  
Preservation of 
body image  
Improved quality of 
life  
 
Slight increase the 
rate of recurrence 
compared to MRM  
Lower acceptance 
among less educated 
people  
Prolonged treatment 
course   
Requires access to 
RT facility    
 
High quality breast 
imaging  
Core surgical 
resources  
Pathology for 
margin assessment   
Surgical services 
experience in the 
procedure 
Breast conserving 
whole breast 
irradiation  
Geographical 
accessibility   
Support system 
that’s allows RT 
over a period of 
weeks  
 
 
 
 
  
TABLE 10 Anatomical structures removed in various types of mastectomy 
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Sub-cutaneous  X           
 
Total (simple) X  X X         
 
Modified simple) X  X X X        
 
Total with axillary 
dissection. 
X  X X X X       
 
Auchincoloss MRM X  X X X X X      
 
Scanlon MRM X  X X X X X X     
 
Patey MRM X  X X X X X X X    
 
Halstead RM X  X X X X X X X X   
 
Urban ERM X  X X X X X X X X X  
 
Dahl-Iversen ERM X  X X X X X X X X X X 
 
Super-radical 
(Wangensteen) 
X  X X X     X X X X X X X X 
 
 
  The contraindications to BCS were determined in 1991 by a panel of 
representatives from the American College of Surgeons, the American 
College of Radiology, the College of American Pathologists, and the Society 
of Surgical Oncology:  
Absolute contraindications to breast-conserving surgery:  
1.Pregnancy: first and second trimester 
2.Multicentricity: two or more gross tumors in separate quadrants 
3.Diffuse undetermined or malignant-appearing microcalcifications 
4.History of previous irradiation to the breast region viz mantle RT 
Relative contraindications to breast-conserving surgery 
1.Large tumor/breast ratio with respect to acceptable cosmetic results 
2.Large breast size 
3.Tumor location beneath the nipple 
4.History of collagen vascular (connective tissue) disease 
 A tumor located beneath the nipple might not be considered a 
contraindicationto breast-conserving surgery if the patient understands the 
anticipated deficit and desires the procedure. Extremely large breast size is 
also not a contraindication to breast-conserving surgery if radiation therapy 
can assure dose homogeneity. 
 In terms of management of the breast the simplest approach would be to 
remove the tumour itself, preferably with a margin of normal tissue around 
it. In theory the more limited procedures of tumourectomy or lumpectomy 
are likely to be followed by a good cosmetic result but are more likely to be 
followed by local recurrence because of the likelihood of failure to excise 
the tumour completely. More extensive forms of conservative surgery such 
as quadrantectomy are more likely to provide good tumour control but are 
more liable to be followed by a less satisfactory cosmetic result because of 
the amount of breast tissue excised. 
 Nearly all of the series evaluating Skin Sparing Mastectomy comprise 
Stage 0, I, and II breast carcinomas. Some have also included a few Stage III 
tumors, which were clinically thought to represent earlier-stage lesions 
preoperatively .Foster et al evaluated outcomes for SSM with immediate 
reconstruction in patients with locally advanced disease, specifically Stages 
IIB and III. With a median follow-up of 49.2 months, the rate of local 
recurrence was 4%, which is comparable to the reported overall local 
recurrence rates in the literature. They concluded that this procedure is safe, 
effective, and has a low 
morbidity on women with locally advanced breast carcinoma SSM can be 
performed for noninvasive or invasive breast cancer. Simmons et al reported 
that among NSSM patients, 62% had modified radical mastectomies, 37% 
had total mastectomies, and fewer than 2% had radical mastectomies; and 
that among SSM patients, 44% had modified 
radical mastectomies, 56% had total mastectomies, and none had radical 
mastectomies . 
 Postoperative adjuvant chemotherapy or radiation therapy is indicated 
based upon the size of the primary tumor and the number of positive axillary 
lymph nodes. A recent study showed that 49% of both NSSM and SSM 
patients received postoperative adjuvant chemotherapy.Postoperative 
radiation therapy is typically given because of a tumor size 
 greater than 5 cm or because of numerous axillary lymph nodes with 
metastatic disease. In one series, it was performed in 3% of SSM and in 
12%of NSSM (P = NS). Although there is some cosmetic disadvantage to 
postoperative radiation therapy in patients who have tissue-expander 
reconstruction, patients with autologous reconstruction often maintain an 
excellent cosmetic outcome. If it is suspected before reconstruction that 
postoperative radiation will be indicated, one option is to create the 
reconstructed breast slightly larger than the contralateral breast, which often 
results in a more symmetrical long-term outcome after radiation. 
 Locoregional radiotherapy should be delivered to the chest wall 
and to the  supraclavicular and axillary nodes. The role of internal 
mammary irradiation is not clear. 
  When locoregional radiotherapy is delivered following MRM for 
locally advanced disease, radiation should be delivered to the chest 
wall,supraclavicular and axillary nodes. Whether treatment to the internal 
mammary nodes is required is unclear. In many of the studies reviewed for 
this guideline, the internal mammary nodes were irradiated. However, there 
are no studies that examined the impact of such radiotherapy. It is not 
unreasonable to include radiotherapy to the internal mammary nodal region, 
provided that this can be done without treating an excessive amount of heart 
or lung tissue. Locoregional radiotherapy has been associated with a modest 
increase in late non-breast-cancer deaths of cardiac or vascular origin. The 
recommended dose of radiation is 50 Gy in 25 fractions or equivalent. 
 
 
Inoperable tumours  
 
• Patients with stage IIIB disease who respond to chemotherapy should 
receive surgery plus locoregional radiotherapy. 
• The locoregional management of patients with stage IIIC disease who 
respond to chemotherapy is unclear and should be individualized. 
• Patients whose disease remains inoperable following chemotherapy should 
receive locoregional radiotherapy and subsequent surgery if feasible. 
The locoregional management of patients with stage IIIC disease who 
respond to chemotherapy is unclear. In the absence of evidence on this 
subgroup of patients, it is reasonable that they receive locoregional 
radiotherapy (including nodal irradiation). The role of completion 
mastectomy should be individualized and based on such factors as response 
to chemotherapy and radiotherapy,absence of metastases on re-staging 
examinations and patient fitness. 
 Patients who are treated primarily with radiotherapy should be given 
tumouricidal doses to areas of bulk disease (60–66 Gy in 30 to 33 fractions 
or equivalent). Higher doses of radiation (70 Gy in 35 fractions by external 
beam or brachytherapy) to areas of bulk disease may be considered for 
patients if surgery is felt not to be an option and if tolerance of critical 
organs permits. Two case series have reported a dose-response relation with 
higher doses of radiation that resulted in decreased rates of local recurrence 
 For the patient who has a partial or complete response to 
chemotherapy and whose lesion is converted to an operable state, the next 
maneuver is typically mastectomy to debulk gross disease, to facilitate local-
regional control, and to allow for the pathologic assessment of response. For 
patients with a complete or partial response, the optimal chemotherapy to 
use after local-regional treatment is uncertain. Specifically, it is not clear 
whether to continue the same chemotherapy as before after local-regional 
treatment or whether a cross-resistant chemotherapeutic regimen is 
indicated. The ASCO guidelines recommend postmastectomy radiation 
treatment, in general, for those patients who require a mastectomy 
 For the patient whose tumor remains inoperable after first-line 
systemic chemotherapy, the options are to proceed with second-line 
chemotherapy or to deliver preoperative radiation treatment. One major goal 
of treatment is to attempt to convert the lesion from an inoperable to an 
operable state, because patients without local-regional control have 
substantially diminished quality of life.  
 According to the St. Gallen conference,node-negative patients with a 
low risk for recurrence should not receive adjuvant chemotherapy. These 
include   
• Node-negative infiltrating ductal or lobular carcinoma 
• Tumor size less than 1 cm 
• Well differentiated (histologic grade 1) 
• ER or PR positive 
• Age of 35 or more 
• Size is less than 3 cm   
      Pure mucinous, tubular, papillary, and adenocystic carcinoma if   
      the tumor Contraindications to therapy (toxicity) 
• Concurrent incurable, terminal illness 
• Severe cardiovascular, hepatic, or renal disease 
• Severe bone marrow deficiency 
• Severe immunodeficiency 
• Mental illness 
 
Locally advanced breast cancer and sentinel node biopsy 
 Clearly, the status of the axillary lymph nodes still has an important 
prognostic role in LABC treated with neoadjuvant protocols. The driving 
question now is when to stage the axilla. Should the axilla be staged prior to 
and/or following neoadjuvant therapy? 
  Feasibility of sentinel node biopsy for LABC 
 Sentinel node biopsy has been extensively studied in early breast 
cancer and has been found to have an accuracy from 92% to 100% with 
successful identification of 90–100%  However, limited experience in 
LABC is only now beginning to emerge and very little experience with 
SLNB after neoadjuvant therapy has been reported. Estimates of the 
accuracy and false negative rates (FNRs) of SLNB based on published tumor 
size suggest that for primary lesions greater than 3.0 cm, the accuracy should 
be as high as 96% . Other groups, have directly evaluated the accuracy of 
SNB in LABC prior to any treatment. Bedrosian et al. evaluated 104 patients 
of whom 87 had T2 and 17 had T3 lesions and a clinically negative axillary 
exam. They were successful in identifying the SN in 99% of the cases with a 
FNR of only 3%. This would suggest that SLNB before neoadjuvant therapy 
is highly accurate for patients with large tumors.  
 Sentinel node biopsy following neoadjuvant treatment of LABC 
 The experience with neoadjuvant chemotherapy and SLNB is limited 
but has been successful in several trials and can be considered on a case-by-
case basis at institutions that have had abundant experience with SLNB and 
neoadjuvant chemotherapy. Clearly the role of SLNB in LABC and 
neoadjuvant therapy has yet to be defined, but certainly this powerful 
diagnostic tool will play a prominent role. 
Table11  Sentinel node following neoadjuvant chemotherapy 
  
Study  Lymphatic 
mapping 
technique  
Neoadjuvant 
treatment  
Tumor 
size  
Rate of SLN 
identification
False 
negative 
rate 
Accuracy 
Nason  Tc sulfur 
colloid  
AC+G  6-T2 
9-T3 
13/15 3/9 10/13 
Breslin Blue dye 
only first 
23 cases  
 
Last 28 + 
TC SC  
FAC  
 
 
 
FAC,TFAC 
Stage 2a-
25 
 
 
2b-12 
3a-14 
11/17 
 
 
 
16/17 
16/17 
3/25 
 
 
 
 
40/43 
HAID  Blue dye + 
TC- ALB  
 
CMF, EC , 
T/E 
2-T1 
30-T2 
1-T3 
29/33 
 
0/29 29/29 
Julian Isosulfan 
Blue / 
TCSC / 
both  
AC,AC+T 11-T1 
20-T2/T3 
 
29-31 0/29 29/29 
Tafra Isosulfan 
Blue / 
TCSC / 
N/A 1.4 Mean 
size 
27/29 0/29 29/29 
Stearns  Isosulfan 
Blue  
AC, A-
T,AC-T 
25-T3 
9-T4 
 
23/26 1/16 22/23 
 
 
Reconstructive surgery in LABC: 
 The goal of reconstructive surgery for patients with locally advanced 
breast carcinoma can be to repair defects or to repair defects and to recreate 
the breast mound. In patients with LABC who need or elect to have standard 
mastectomy and who desire breast reconstruction to improve the cosmetic 
outcome, reconstruction is often delayed until completion of  both adjuvant 
chemotherapy and irradiation. As most locoregional recurrences are in the 
skin or subcutaneous tissue of chest wall a flat post-mastectomy defect often 
makes irradiation technically easier than does a reconstructed breast mound, 
especially if the inclusion of the internal mammary nodal basin is necessary. 
However in selected patients with excellent response to induction 
chemotherapy or when palliative debulking surgeries are needed, the use of 
an autogenous flap to create a breast mound or provide skin coverage of the 
operative defect before radiotherapy is instituted if feasible. 
 The use of a myocutaneous flap for breast reconstruction, either 
before or after irradiation, does not interfere with the resumption of 
chemotherapy or the ability to detect locoregional recurrence. Irradiation of 
the reconstructed breast mound flap does not impair the flap’s blood supply. 
Provided that the flap has an adequate vascularisation without evidence of 
significant fat necrosis, the irradiation itself does not alter the cosmetic result 
except for the anticipated skin tanning and slight fibrosis of the 
reconstructed breast mound . 
 The  two tissue flaps that have been most frequently used for breast 
reconstruction are the lattissimus dorsi and rectus abdominis myocutaneous 
flaps. The advantages of the Latissimus dorsi flap include its reliable blood 
supply ant the relative rarity of donor site morbidity.The flap is also 
relatively thin and so matches the thickness of the native chest wall skin 
fairly closely and also provides excellent soft tissue coverage. The chief 
disadvantage of the Latissimus dorsi flap is its limited size;an implant is 
usually required if the patient desires a reconstructed breast mound. 
 The Rectus abdominis myocutaneous flaps can be quite large and are 
most useful for defects too large to repair with a LD flap. The chief 
disadvantage is that they tend to be bulky and thus do not closely match the 
thickness of the native chest wall skin. The thickness of the flap can be an 
advantage, however if the defect is located directly over the central area of 
the chest wall;in this case the excess flap may be utilized to reconstruct a 
breast mound.  
 The two main types of Rectus abdominis myocutaneous flaps are the 
transverse rectus abdominis myocutaneous flap(TRAM) and the vertical 
rectus abdominis myocutaneous flap(VRAM).The TRAM flap has a greater 
arc of rotation and a more symmetrical and easiliy concealed donor site than 
does the VRAM flap.The VRAM flap leaves a more noticeable donor scar 
but is easier to construct and has a more reliable blood supply. 
 For major chest wall resections,the rectus abdominis flap is capable of 
covering a wide area from the clavicle to the costal margin and from the 
sternum to the midaxillary line.Because the flap is bulky,it provides 
sufficient chest wall stability even when upto five ribs or the entire sternum 
is resected, without the need for prosthetic mesh. Marlex,a nonabsorbable 
durable mesh can be used for flat surfaces of the chest wall. If the defect is 
large,a sandwich of  Marlex and methyl methacrylate can be formed to 
restore a more normal contour. If the mesh is covered by well vascularised 
tissue, the risk of infection and extrusion is usually low. 
Immediate breast reconstruction (IBR) is now recognized as an esthetically 
acceptable and oncologically safe treatment option for many early-stage 
breast cancer patients 
who undergo mastectomy. However, patients with locally advanced breast 
cancer (LABC) historically have been considered poor candidates for IBR 
for several  
reasons: (1) concerns regarding increased risk of local recurrence (LR) and 
possible delays in detecting LR; (2) concerns that prolonged recovery from 
extensive surgery would result in delays in postoperative chemotherapy ; (3) 
concern about a possibly higher risk of wound infections in patients who 
have received preoperative chemotherapy; and (4) concerns regarding the 
technical difficulties of irradiating the reconstructed breast. Despite these 
issues, IBR has been performed in many women with LABC, because of (1) 
strong patient preference, unclear preoperative assessment of extent of 
disease, or (3) need to provide soft tissue coverage for an extensive 
mastectomy defect. 
 
 
 
 
 
 
 
INFLAMMATORY BREAST CARCINOMA 
 In 1814, Sir Charles Bell first recognized the clinical evolution of IBC 
when he wrote: "a purple color on the skin over the tumor accompanied by 
shooting pains, is a very unpropitious beginning.”Later in the nineteenth 
century, Klotz described ”mastitis carcinomatosa” as a variant of carcinoma 
of the breast characterized by its fulminant course.” In 1889, Bryant reported 
the association of dermal lymphatic invasion with the clinical characteristics 
of 1BC.’ The term inflammatory was coined by Lee and Tannenbaum in 
1924.T heir paper was the first to describe in great detail the clinical 
characteristics of IBC in a series of 24 patients.Several other names have 
been used to describe this entity including carcinoma mastitoides, 
carcinoma e ysipeloides, lactation cancer, and malignant 
lymph~ngitisB.~e~tw een 1908 and 1911, the term acute carcinoma was 
used by several investigators, and Leitch, in 1909, introduced the french 
term “peau d’orange” in an English literature paper. Taylor and Meltzer 
subsequently described two clinical varieties of inflammatory breast cancer: 
(1) Primary inflammatory breast cancer, characterized by a sudden onset of 
the above symptoms in a breast which previously appears normal; 
(2) Secondary inflammatory breast cancer, defined by inflammatory 
symptoms and signs which appear in a breast with a previous mass, in the 
chest wall postmastectomy 
or in the contralateral breast . 
  Inflammatory breast cancer is a distinct clinical subtype of locally 
advanced breast cancer, with a particularly aggressive behavior and poor 
prognosis. Clinically, inflammatory breast cancer typically presents with the 
rapid onset of breast erythema, warmth, and edema, often without a discrete 
underlying mass. The swelling of the breast can be quite pronounced, 
producing significant tenderness.Although histologic proof of malignancy is 
critical prior to treatment of IBC, documenting dermal lymphatic permeation 
is not critical in establishing the diagnosis of IBC. 
 IBC is defined under the current American Joint Committee on 
Cancer (AJCC) manual for staging of cancer as T4d NO-2 stage III b, 
carcinoma of the breast. This corresponds to Haagensen’s stage D of the 
Columbia Clinical Classification. Bonnier et al. classified patients into three 
groups according to clinical and histopathological features  
Group A included patients with typical inflammatory breast cancer (diffuse 
enlargement of the breast, often no palpable tumour, redness and oedema of 
the skin).Ipsilateral enlargement of the axillary nodes was often detected and 
emboli of carcinoma cells in the subdermal lymphatics were often found. 
Group B included patients with occult inflammatory breast cancer, in which 
the presence of tumour emboli in dermal lymphatics was not associated with 
inflammatory symptoms and signs. 
Group C included patients with pseudo-inflammatory breast cancer. 
Symptoms were similar to those of groupA. However a tumour mass was 
more readily palpable and the sub-dermal lymphatics were never 
involved.Furthermore, the axillary nodes were rarely involved. 
Evaluation of IBC 
 Evaluation of patients presenting with IBC must be 
multidisciplinary.This includes a thorough documentation of physical 
findings and extent of disease, including axillary and supraclavicular lymph 
node enlargement. Bilateral mammograms are performed to ensure that this 
is a unilateral process and as a baseline for future reference. Although core-
needle biopsy affords the most efficient proof of malignancy, we prefer an 
incisional biopsy including skin to determine dermal lymphatic involvement 
. Hormone receptor analysis, DNA content, and Sphase fraction are routinely 
perfornted. Metastatic work-up includes CT scans of the chest and upper 
abdomen, including liver and adrenalglands; bone scintigraphy; liver 
enzymes; and carcinoembryonic antigen determination.Bryant" attributed 
the inflammatory signs in this type of cancer to diffuse lymphatic blockage 
by cancer cells, but this finding is not specific for IBC. Inflammatory breast 
cancer exhibits all the usual microscopic features of infiltrating ductal 
carcinoma. IBCs are poorly differentiated and without evidence of glandular 
formation.  
  Neglected locally advanced breast cancer can develop secondary 
inflammatory characteristics, but should be distinguished from primary 
inflammatory carcinoma as these secondary inflammatory breast cancers 
may follow a more indolent course and can be treated as other locally 
advanced breast tumors.  Three biological features make inflammatory breast 
cancer a unique clinical entity : 
(1) Rapidity of progression 
(2) High angiogenic and angioinvasive capability 
(3) Aggressive behaviour from inception. 
 van Golen et al. found that overexpression of RhoC GTPase and the lost in 
inflammatory breast cancer (LIBC) protein were highly correlated with an 
inflammatory breast cancer phenotype. These tumors are more likely to be 
high grade, aneuploid, and hormone-receptor negative and have a high S-
phase fraction and p53 mutations. Despite these differences in biologic 
characteristics, prognostic factors for inflammatory breast cancer are similar 
to those for locally advanced disease, with axillary lymph node involvement 
predicting poorer survival. Other negative prognostic factors for 
inflammatory carcinoma include negative ER status, extensive erythema of 
the breast, and p53 mutations.  
 Management of IBC 
 The optimal treatment of inflammatory breast cancer requires careful 
coordination of multimodal therapy among medical, radiation, and surgical 
oncologists.Current treatment for inflammatory breast cancer centres upon 
neoadjuvant chemotherapy. The advent of neoadjuvant chemotherapy has 
greatly improved disease-free and overall survival for inflammatory breast 
cancer  Ueno et al., in their series of 178patients, report overall survival of 
40% at 5 years and 33% at 10 years. Given that inflammatory breast cancer 
metastasises early, sub-clinical systemic disease is likely to exist, which may 
be controlled by neoadjuvant chemotherapy. The initial component of 
treatment hence should be induction chemotherapy with an anthracycline-
based regimen or an anthracycline and taxane combination. Definitive local 
therapy can then be achieved with radiation therapy, mastectomy, or both. .  
After local therapy, patients should receive further adjuvant chemotherapy, 
as the risk of relapse remains high, followed by adjuvant radiotherapy, if not 
previously given. 
 Role of surgery in IBC 
 Early experience with surgery for inflammatory breast cancer was 
uniformly disappointing, with high rates of recurrence and poor overall 
survival. The role of surgery is now being re-evaluated due to the 
effectiveness of neoadjuvant chemotherapy, whichhas resulted in 
downstaging of disease with decreased tumour burden . This provides a 
greater opportunity for adequate surgical resection.Curcio et al.found that  a 
successful outcome for surgery for inflammatory breast cancer following 
neoadjuvant chemotherapy depended upon achieving negative excision 
margins. Lopez and Porter  noted that consistently achieving tumour-free 
resection margins can be technically difficult in inflammatory breast cancer 
patients, and may require complex reconstructions with myocutaneous flaps 
and extensive cutaneous dissection. Breast conservation is rarely possible.  
 
 
 
 
 
 
 
 
 
 
 
TABLE 12 RETROSPECTIVE STUDIES OF CHEMOTHERAPY  FOR 
INFLAMMATORY  BREAST CANCER 
 
Authors  Year No of 
patients 
Treatment 
regimen 
Response 
rate (%) 
Median 
survival   
(Months) 
5 years 
survival 
(%)  
5 years 
survival 
(%) 
DeLena   1978 36 CT+RT+CT 67 25 24 NA 
Pawlicki 1983 72 CT+S+RT 70 NA 28 NA 
Keiling 1985 41 CT+S+CT NA NA 63 NA 
Roueesse 1989 170 CT+RT+CT+H 74 Na 47 NA 
Koh 1990 106 CT+S+RT+CT 69 45 38 NA 
Mailosel 1990 43 CT+S+CT+RT+H 88 46 75 NA 
Moores 1991 38 CT+S+RT 79 56 45 NA 
Picrce 1992 46 CT+H+S+RT 98 NA 36 NA 
Chevallier 1993 178 CT+RT+CT+S 71 37 32 NA 
Palangie 1994 223 CT+RT NA 41 41 NA 
Perez 1994 86 CT+S+RT NA 36 40 35 
Ueno 1997 178 CT+RT+S+CT NA NA NA 28 
Harris 2007 54 CT+RT+S NA 62 56 35 
 
 Sentinel lymph node biopsy may also be unsuitable in the setting of 
inflammatory breast cancer due to the high level of nodal involvement found 
in this disease. Also since cancer infiltrates the dermis and lymphatics in 
inflammatory breast cancer, the underlying architecture may be disrupted to 
the extent that sentinel lymph node biopsy is not of value Relatively few 
women with inflammatory breast cancer have been offered reconstructive 
surgery following surgery . Concerns about reconstruction include delays to 
adjuvant treatment, difficulty in the detection of recurrence and increase in 
morbidity. Given the improved multimodality treatment of inflammatory 
breast cancer, reconstructive 
procedures should be offered as part of comprehensive therapy, as long as a 
positive margin at resection is not expected(Chin et al). The exact 
indications for surgery and the optimal operation, however, remain unclear. 
 Radiotherapy was the mainstay of care for inflammatory breast cancer 
for many years, but the results were unimpressive. Radiotherapy alone has 
been shown to improve local control rates in treatment of inflammatory 
breast cancer, but to have no effect on survival  Since the introduction of 
neoadjuvant chemotherapy, and the return of surgery, 
radiotherapy is now seen as an important part of a multimodality treatment 
approach, rather than treatment on its own. The importance of radiotherapy 
relates primarily to its function in loco-regional control. 
No substantial improvement in survival from hormone therapy for 
inflammatory breast cancer has been shown , which is not surprising given 
that patients with inflammatory breast cancers are more frequently oestrogen 
and progesterone receptor negative compared with other breast cancers. 
Nevertheless, if the tumour is oestrogen receptor positive it is currently 
advised that patients receive 5 years of treatment with either tamoxifen or 
aromatase inhibitors. 
 Recent discoveries of the distinct biologic features that characterize 
inflammatory carcinoma can lead the way toward the development of new 
therapies. For instance, farnesyl transferase inhibitors have been shown to 
reverse the invasive phenotype of RhoC GTPase-overexpressing cell lines. 
Other possible therapeutic targets include mediators of angiogenesis such as 
vascular endothelial growth factor, basic fibroblast growth factor, and Flt-1, 
which are overexpressed in inflammatory breast cancers.  
 
Allocation of resources : 
 
 The treatment of breast cancer requires an integrated, 
multidisciplinary approach using multiple resources in a focused, disease-
oriented manner. Existing evidence-based 
guidelines outlining optimal approaches to the treatment of breast cancer 
have been defined and disseminated, but do consider the multiple deficits in 
infrastructure and the availability of therapies in limited-resource countries. 
Marked heterogeneity exists among countries and also between regions of 
the same country with regard to social, economic, and health system 
development. Therefore a uniform approach for all limited-resource 
countries is neither practical nor realistic. The BHGI has proposed a 
stepwise, systematic approach for building national or regional breast health 
treatment systems by stratifying health care resources into four levels—
basic, limited, enhanced, and maximal—based on the contribution of 
incremental resources in improving clinical outcomes. 
 
 
 
 
 
Table13  Treatment and Allocation of Resources: Locally Advanced Breast Cancer 
 
Local-regional Treatment Systemic Treatment (Adjuvant)Level of 
Resources Surgery Radiation Therapy Chemotherapy Endocrine 
Therapy 
Basic Modified radical 
mastectomy 
  Neoadjuvant AC, 
FAC, or classical 
CMFa 
Ovarian 
ablation  
 
Tamoxifen  
Limited   Postmastectomy 
irradiation of the chest 
wall and regional nodes 
    
Enhanced Breast-
conserving 
therapyb 
Breast-conserving 
whole-breast irradiation
Taxanes Aromatase 
inhibitors  
 
LH-RH 
agonists  
Maximal Reconstructive 
surgery 
  Growth factors  
Dose-dense 
chemotherapy  
  
aRequires blood chemistry profile and complete blood count (CBC) testing. 
bBreast-conserving therapy requires mammography and reporting of margin 
status. 
AC, doxorubicin and cyclophosphamide; CMF, cyclophosphamide, 
methotrexate, and 5-fluorouracil; EC, epirubicin and cyclophosphamide; 
FAC, 5-fluorouracil, doxorubicin, and cyclophosphamide; LH-RH, 
luteinizing hormone releasing hormone. 
 
 
SURVEILLANCE/FOLLOW-UP 
 
 Despite advances in the multidisciplinary approach in the 
management of locally advanced breast cancer that has improved the 
prognosis as well as the quality of life  considerably ,the overall survival 
remains almost constant.That the prognosis is stage dependant has been well 
established. 
 
 Interval history and physical exam every 4-6 months for 5 years, then 
every 12 months Mammogram every 12 months (and 6-12 months post-RT 
if breast conserved)  
Women on tamoxifen: annual gynecologic assessment every 12 months if 
uterus present Women on an aromatase inhibitor or who experience ovarian 
failure secondary to treatment should have monitoring of bone health Assess 
and encourage adherence to adjuvant hormonal therapy. 
 Patient education on recurrence, morbidity of treatment ,psycho social 
aspects,prosthesis before ,during & at completion of treatment  
Breast self examination – monthly 
Haematology,Bioprofile,Imaging 
Assay   for tumour markers                             not recommended routinely            
AIMS & OBJECTIVES  
1. To ascertain the incidence of LABC among the women presenting 
with breast cancer. 
2. To define the optimal treatment for women with stage III or locally 
advanced breast cancer (LABC). 
3. To ascertain the feasibility of the defined optimal treatment and to 
advocate it among patients with LABC. 
Period of study : May 2005 – October 2007 
Methods 
 
 We conducted a  review of the literature in the English-language  retrieved 
from internet and medical journals regarding the management of locally 
advanced breast cancer.Search terms used were “breast neoplasms,” “locally 
advanced breast cancer,” “stage III breast cancer,” “drug therapy,” “neo-
adjuvant,” “primary systemic therapy,” “radiotherapy or irradiation,” 
“surgery,” “randomized trials” and “high-dose therapy.”  Additional data 
were identified by reviewing references in retrieved reports and by 
monitoring major conferences on breast cancer. The main outcomes 
considered are  locoregional control (defined as freedom from recurrence in 
the breast, chest wall or regional lymph nodes), disease-free survival (DFS; 
defined as survival free of breast cancer recurrence) and overall survival 
(OS). 
   Numerous setbacks encountered in the process of synthesizing the results 
of the studies from the review of the literature included : 
1. Majority of the studies were from the western population that differed 
vastly from the Indian scenario. 
2. The studies included different populations of patients with differing 
prognoses; for  example, some studies included patients with 
inflammatory breast cancer whereas other studies did not. 
3. In studies evaluating systemic therapies, local therapy 
(surgery/radiotherapy) was often not standardized. 
4. The TNM tumour-staging system changed, in that tumours associated 
with ipsilateral supraclavicular nodal involvement that were initially 
considered LABC were considered metastatic breast cancer between 
1987 and 2002 and are now considered LABC again. 
5. The randomized trials that were available were old, had small patient 
numbers and used systemic therapy combinations that are often not 
used today. 
6. The various recent advances available as of today could not be 
utilized in the study owing to patient’s socioeconomic ceiling.For 
example hormone receptor assay /her-2 neu assay /bone scan could 
not be advocated. 
7. Breast reconstruction / breast conservation could not be tried for the 
lack of infrastructure and patient compliance. 
Patients and methods 
 Between May 2005 and October 2007, a total of  43 cases of 
carcinoma breast were admitted in our surgical unit in the Government 
Rajaji Hospital,Madurai.All of those admitted were staged according to the 
AJCC TNM  classification. Staging work-up 
consisted of a complete bloodcount (CBC), blood chemistry, chest X-
ray,and ultrasonography of the liver.Either FNAC/ Trucut / incisional biopsy 
were used to confirm the diagnosis of carcinoma breast.of the 43 patients, 
 one of them was of male sex ; 42 were of female sex.For all practical 
purposes only the 42 female breast carcinoma were considered for the study. 
18 were right – sided & 24  left-sided, one of stage I ; four of stage II ; 29 of 
stage III ; 8 of stage IV.  
Of the 30 cases of LABC, (29 of III & 1 of II) 
one of them was inflammatory carcinoma 
18 were  post – menopausal & 12 were pre- menopausal. 
The HPE in all the cases were of infiltrating ductal carcinoma.Since ER 
status could not be ascertained,all of the cases were considered ER + for all 
practical purposes.  
All of the cases of LABC except for the inflammatory carcinoma  underwent 
modified radical mastectomy,followed by adjuvant chemoradiation & 
Hormonal therapy .Adjuvant chemotherapy consisted of 6 cycles of CAF 
regimen.Adjuvant radiation included EBRT of 5000 Gy to the tumour bed & 
nodal basins.Receptor status could not be ascertained. So, the receptor status 
was considered positive for all practical purposes and adjuvant hormonal 
therapy in the form of tamoxifen 10 mg bd was instituted for a period of 5 
years. 
 
 
 
 
CONCLUSIONS 
 The incidence of LABC among the study population was 
approximately 69%.LABC forms the majority of  the cases of  breast cancer  
at the time of initial presentation itself.The significance of this conclusion is 
that what cases are classified at a specific instance as LABC once belonged 
to the category of early breast cancer and subsequently evolved into LABC 
due to either  patient’s negligence or inappropriate intervention  or 
aggressive tumour biology.Thus as prevention is always better than cure it is 
recommended that the following measures can be adopted to address this 
problem : 
1. Health education regarding self breast examination 
2. Screening mammography 
3. Identifiation of high risk population and specific management 
4. Surveillance when family history is positive for breast 
cancer.Metastatic work-up is mandatory. 
Hormone receptor assay may be useful in planning treatment  
For better management of patients with LABC, the following is 
recommended: 
• Early diagnosis of breast cancer is vital for better results of treatment. 
General education about early symptoms of the disease and access to 
medical facilities are important in diminishing breast cancer mortality in our 
country. 
• Cellular biological markers such as Her-2, P53, etc. should be evaluated as 
prognostic factors in prospective randomized studies. 
• Randomized trials are recommended for comparing new adjuvant regimens   
 Lack of treatment compliance and/or failure to provide standard-of-care 
treatment in high-risk breast cancer can lead to a higher incidence of 
metastatic cancer and mortality.  
         
                       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In 1943, Haagensen and Stout  identified “grave clinical signs” predicting poor outcome 
in women with primary breast cancer treated with radical mastectomy. These features 
include the presence of extensive skin edema, satellite nodules, intercostal or parasternal 
nodules, arm edema, supraclavicular metastasis, inflammatory carcinoma, or distant 
metastasis, or the presence of two or more of the following: ulceration of the skin, skin 
edema of limited extent (more than one-third of the breast), fixation to the chest wall, 
axillary lymph nodes larger than 2.5 cm, or fixation of axillary lymph nodes to the skin or 
deep structures of the skin. Other clinical signs of locally advanced disease included a 
single tumor larger than 10 cm in size, multiple tumors in one breast, redness of the skin, 
and skin involvement.  This classical description of the clinical contraindications to the 
primary surgical management of primary breast cancer is, in general, still valid today. In 
Haagensen's series of patients with these grave signs, local recurrence rates were 42% 
despite radical mastectomy, and no patient survived disease-free for 5 years. Patients with 
these characteristics (and having no distant metastases) are currently included in the 
category of locally advanced breast cancer (LABC). The poor outcome of these patients 
when treated with radical mastectomy led to the investigation of other treatment 
strategies. 
The definition of LABC has evolved from that of Haagensen and Stout, to encompass a 
 wide spectrum of clinical presentations: 
• Large tumors (>5 cm) 
• Extensive regional lymph node involvement 
• Direct involvement of the underlying chest wall or skin with edema (including 
peau d'orange) or ulceration or satellite skin nodules confined to the same breast. 
Other discrete skin changes, such as dimpling or nipple retraction, may occur in 
T1-3 disease; they do not constitute evidence of a locally advanced tumor. 
• Tumors considered inoperable but without distant metastasis (including 
involvement of the supraclavicular lymph nodes) 
• Inflammatory breast cancer (IBC) 
Acording to the AJCC staging,LABC comprises of :  
T3 Tumor more than 5 cm in greatest dimension  
T4 Tumor of any size with direct extension to a. Chest wall or b. Skin 
T4a Extension to chest wall, not including pectoralis muscle  
T4b Edema (including peau d’orange) or ulceration of the skin of the breast, or satellite 
skin nodules confined to the same breast 
T4c Both T4a and T4b  
T4d Inflammatory carcinoma  
Regional Lymph Nodes (N) 
NX Regional lymph nodes cannot be assessed (e.g., previously removed) 
N0 No regional lymph node metastasis 
N1 Metastasis in movable ipsilateral axillary lymph node(s) 
N2 Metastases in ipsilateral axillary lymph nodes fixed or matted, or in clinically 
apparent(1) ipsilateral internal mammary nodes in the absence of clinically evident 
axillary lymph node metastasis 
N2a Metastasis in ipsilateral axillary lymph nodes fixed to one another (matted) or to 
other structures  
N2b Metastasis only in clinically apparent(1) ipsilateral internal mammary nodes and in 
the absence of clinically evident axillary lymph node metastasis 
 
N3 Metastasis in ipsilateral infraclavicular lymph node(s) with or without axillary lymph 
node involvement, or in clinically apparent(1) ipsilateral internal mammary lymph 
node(s) and in the presence of clinically evident axillary lymph node metastasis; or 
metastasis in ipsilateral supraclavicular lymph node(s) with or without axillary or internal 
mammary lymph node involvement 
N3a Metastasis in ipsilateral infraclavicular lymph node(s)  
N3b Metastasis in ipsilateral internal mammary lymph node(s) and axillary 
lymph node(s)  
N3c Metastasis in ipsilateral supraclavicular lymph node(s)  
 T4 is defined as a tumor of any size  
with direct extension to chest wall, not including pectoralis muscle. 
T4b
 
 A. T4b, illustrated here as satellite skin nodules, is defined as edema 
(including peau d’orange) or ulceration of the skin of the breast, or satellite skin 
nodules confined to the same breast. B. T4b illustrated here as edema (including 
peau d’orange). 
 
 
 
 T4c is defined as both T4a and T4b.                   T4d, inflammatory carcinoma. 
  Table 1 : Stage Grouping of Carcinoma Breast. 
 
Note: Stage designation may be changed if post-surgical imaging studies reveal 
the presence of distant metastases, provided that the studies are carried out 
within 4 months of diagnosis in the absence of disease progression and provided that the 
patient has not received neoadjuvant therapy. 
 All T and N permutations included in stage IIB, III or IV comprised many distinct 
substage possibilities. The presence of T4 or N3 or regional M1 lesions would result in 
inclusion in the stage IIIB/IV unresectable subcategory. Most of the patients with either 
T3 or N2, but without T4, N3 or regional M1 lesions, are included in the stage II/IIIA or 
operable subcategory. LABC also includes T2 tumors that are too large in proportion to 
the size of the breast.In the most recent TNM staging system, tumours associated with 
ipsilateral supraclavicular nodal basin have been eliminated from the LABC category 
because the supraclavicular nodal basin lies outside the primary lymphatic drainage 
pathways of axilla and internal mammary nodes;tumours associated with supraclavicular 
nodes have been reclassified as stage IV disease.However as the patients with distant 
metastases confined to the supraclavicular  nodes have a better prognosis than patients 
with metastases at other sites and can be rendered disease free with locoregional 
therapy,metastases limited to the ipsilateral sub-supraclavicular fossa have been included 
in the category of LABC defined here. 
LABC is a heterogeneous group of tumors of varying clinical presentations and biological 
behavior whose only common bonds are the presence of a large primary tumor, or 
extensive regional lymph node involvement, and the absence of any evidence of distant 
metastases. Some patients have a rapid neoplastic evolution, whereas others present with 
a long history of tumor growth. 
The clinical diagnosis of LABC is usually not difficult. Patients uniformly present with a 
large breast mass. Other symptoms often reported are edema, redness, nipple retraction, 
pain, skin dimpling, an axillary mass and breast ulceration. Most physical findings are 
obvious upon inspection or palpation. However, in younger women, some tumors 
infiltrate the breast diffusely and a discrete mass is difficult to palpate. More than 75% of 
patients have clinically palpable axillary and/or supraclavicular adenopathy, and 65%-
90% of patients have pathologically confirmed lymph node metastasis; >50% have more 
than four nodes involved. Most of the LABCs are operable; only 25%-30% are diagnosed 
at an inoperable stage. 
A physical examination, bilateral mammogram and ultrasound of the breast and its 
draining lymphatics determine the extent of involvement within the breast and the nodal 
chains, the presence of additional tumor foci within the same breast or the contralateral 
breast, and the extension of the tumor to deeper structures.  
A core needle biopsy is quite effective in establishing the diagnosis and also allowing 
tumor samples to be obtained for hormone receptors, DNA studies and other biomarkers. 
The sensitivity and specificity of fine-needle aspiration are quite high in LABC. The only 
disadvantages of cytological diagnosis are the inability to differentiate between in situ 
and invasive carcinoma, and scant material on which to perform additional studies. 
Excisional biopsies are not indicated in patients with LABC. 
 
Appropriate staging procedures should be performed in patients with LABC since the 
probability of distant metastases is high. Approximately 20% of these patients, 
appropriately staged, have detectable distant metastases at the time of diagnosis.So after a 
complete history, a physical examination should be performed with great attention to the 
evaluation of both breasts and all surrounding lymph node-bearing areas. All tumors 
should be described by the longest perpendicular diameters in cm, and the presence of 
palpable axillary, supraclavicular and subclavicular nodes, with exact measurements of 
their longest perpendicular diameters, should be included. A close-up photograph is 
useful in the staging of patients with T4 tumors. Ideally, the initial evaluation should be 
done simultaneously by the medical oncologist, surgical oncologist and radiotherapist.  
 
After the physical examination and bilateral mammogram, the following additional tests 
are recommended: a biochemical profile, including tests of liver and renal function, and 
calcium level; chest x-ray; bone scans; radiographs of areas that appear to be abnormal on 
the bone scan; computed tomography of the liver and an ultrasonography of the breast 
and regional lymph nodes to precisely assess the tumor extent. The importance of an 
accurate initial assessment of the extent of primary tumor burden cannot be 
overemphasized since the efficacy of subsequent local treatment will depend mostly on 
this initial assessment.  
Patients with LABC are at great risk for morbid local complications of their disease, 
including skin breakdown, tissue necrosis, bleeding, pain, and infection. These problems, 
which may not alter survival, significantly compromise quality of life. Patients with 
locally advanced breast cancer also have a very high rate of systemic micrometastasis at 
diagnosis, which if untreated will progress and lead to organ dysfunction and death. 
There are thus two central goals in the treatment of LABC:  
obtaining and maintaining local control with surgery and/or radiotherapy,  
 improving overall survival by control of systemic disease with chemotherapy and/or 
hormonal therapy. 
Arriving at a uniform treatment plan for LABC is limited by the biologic diversity of the 
disease (there are 13 possible combinations in the current TNM staging system  for stage 
III breast cancer ranging from minute tumors with bulky axillary disease to large tumors 
with microscopic axillary disease). 
Historical perspective & Review of literature.: 
During the last 60 years, the management of LABC has evolved considerably. Initially, 
patients with LABC were treated with radical mastectomy.Based on the disappointing 
results of surgery and radiotherapy in patients with LABC, and the early promising 
results of adjuvant systemic therapy in women with axillary node-positive breast cancer, 
systemic therapy was subsequently incorporated along with surgery and radiotherapy into 
the management of patients with LABC, termed “combined modality therapy.” Even with 
such combined modality therapy, the long-term survival rate is approximately 50% 
among patients with LABC.  
 
 
 Surgery and LABC : 
For many years, the Halsted radical mastectomy was the standard treatment for breast 
cancer.The pioneering work of McWhirter et al in the mid 20th century showed that less 
mutilating surgery produced results equal to that of radical mastectomy.The failure of 
halstedian principle of en-bloc extirpation of the breast and draining lymph nodes to cure 
many patients of breast cancer,frequent identification of small breast cancer by 
mammography,and success of moderate doses of  radiotherapy in eliminating sub clinical 
foci of  breast cancer led to the development of  MRM .MRM is a term used to describe a 
variety of surgical procedures,but all involve complete removal of the breast and some of 
the axillar nodes. Table 3 summarizes the results of surgery alone in the treatment of 
LABC; these studies were retrospective and did not follow uniform staging 
classifications. Some included stage I1 patients in addition to LABC, and some patients 
were treated with radiation therapy and chemotherapy. These studies confirmed that 
surgery alone was inadequate treatment Even with aggressive surgical techniques,patients 
with advanced local disease had a high incidence of localregional recurrence. Most 
important, surgery did not change the pattern of distant failure in patients who probably 
had micrometastatic disease 
The advent of radiation therapy in LABC  
The use of radiation therapy alone in the treatment of locally advanced noninflammatory 
breast cancer was no more effective than surgery alone (Table 4). The local recurrence 
rates of 36% to 72% were even higher than those reported for surgery alone. This 
difference in local-regional failures was no longer evident when patients were treated 
with a combination of radiation therapy and surgery, which suggested that the two 
treatment modalities might provide better results if used together. The patients’ high rate 
of distant relapse, however, emphasized the need for systemic therapy as well. 
 
 
 
 
 
 
 
Combined Surgery and Radiation Therapy 
 
In early attempts to improve locoregional control in treating patients for LABC, radiation 
therapy was combined with surgical therapy. Although these studies showed promising 
results in locoregional control, they failed to address the systemic nature of LABC, and 
patients still died of metastatic disease. The lessons learned in those years emphasized the 
need for additional treatment modalities. First, even though combined radiation and 
surgical therapy delayed the time to first local-regional relapse, there was no significant 
survival advantage. Second, preoperative radiation therapy was often able to convert an 
inoperable breast cancer to an operable one. Third, preoperative radiation therapy did not 
seem to differ from postoperative radiation in providing additional locoregional control. 
Last, a combination of surgery and radiation therapy provided the maximum chance for 
locoregional control over high-dose radiation therapy or surgery alone. Table 5 
summarizes selected series in which combination surgery and radiation therapy were 
used pre or postoperatively to treat LABC patients. The results showed that even 
combining radiation therapy and surgery did not eliminate locoregional failures. 
 
MULTIMODAL THERAPY 
 
Haagensen and Stout's early paper on the criteria of operability in carcinoma of the breast 
made clear that the vast majority of patients with locally advanced disease would develop 
distant metastatic disease. This has been confirmed in multiple trials of surgery and 
radiation therapy alone or in combination.Multimodality  therapy that included surgery, 
radiation therapy, chemotherapy, and hormonal therapy has had the greatest impact on 
survival.   
. 
 
Multidisciplinary approach to LABC : 
 
The clinical management of LABC is complex and should be tailored to the individual 
patient. Frequently, surgery, radiotherapy and systemic therapy (chemotherapy, hormone 
therapy) are used. A multidisciplinary approach to LABC is recommended in which 
treatment is based on the combined opinions of a surgeon, radiation oncologist and 
medical oncologist. The initial management of LABC requires histological confirmation 
(e.g., core biopsy, incisional biopsy or skin biopsy) for diagnosis and for determination of 
hormone receptor and HER-2 neu oncogene status. Cytological evaluation by fine-needle 
aspiration is insufficient. 
                   
LABC
Treatment pathways
Clinically stage IIIA, IIIB, & IIIC Breast cancer
WORK UP
Operable 
Stage IIIA 
Inoperable Stage IIIA & 
stage IIIB
Neoadjuvant therapy(3-4 cycles)
Response No response
Operable Inoperable 
Individualised
therapySurgery 
               
     
Systemic therapy: chemotherapy 
 
Operable tumours • Patients with operable stage IIIA disease should be offered  
 
chemotherapy. They should receive adjuvant chemotherapy following surgery, or  
 
primary chemotherapy followed by locoregional management.  
 
Patients with stage IIIA breast cancer have potentially operable tumours. There are 2 
approaches for treating these patients. The first is modified radical mastectomy (MRM) 
followed by adjuvant systemic therapy and radiotherapy, and the second is preoperative 
chemotherapy followed by surgery and adjuvant chemoradiation. 
. 
                      
LABC - Management protocol
Operable LABC
Desires breast 
conservation
Does not desire breast 
conservation
Pre operative 
chemotherapy
No response after 3-
4 cycles or 
progressive disease
Partial response 
– lumpectomy 
not possible
Complete response 
or partial response 
with lumpectomy 
possible
Lumpectomy with adjuvant 
chemotherapy, radiotherapy & 
hormone therapy
Mastectomy with adjuvant 
chemotherapy, radiotherapy    
& hormone therapy  
Choice of chemotherapy 
 
• Chemotherapy should contain an anthracycline. Acceptable regimens are 6 cycles 
of FAC, CAF, CEF or FEC. Taxanes are under intense investigation 
 
Randomized trials have confirmed the superiority of anthracycline-containing regimens 
such as  CEF and CAF over conventional CMF in women with node-negative and node-
positive breast cancer. In contrast, in the National Surgical Adjuvant Breast and Bowel 
Project (NSABP) B-15 trial, 4 cycles of AC chemotherapy was equivalent to 6 months of 
CMF. Although there are limitations to crossstudy comparisons, it is reasonable to 
consider that 4 cycles of AC, although equivalent to 6 months of CMF, is probably 
inferior to 6 cycles of anthracycline-containing drug regimens such as FAC, CAF, CEF 
and FEC. In women who cannot receive anthracyclines because of underlying cardiac 
disease, CMF chemotherapy can be considered. 
Six cycles of chemotherapy should be administered. This is based on the trials of 
adjuvant chemotherapy that showed that 6 cycles of CAF or CEF was superior to 6 cycles 
of CMF and that 6 cycles of FEC were superior to 3 cycles of FEC.  
NON-TRASTUZUMAB CONTAINING REGIMENS (all category 1) 
 
FAC/CAF (fluorouracil/doxorubicin/cyclophosphamide)  
FEC/CEF (cyclophosphamide/epirubicin/fluorouracil) 
AC (doxorubicin/cyclophosphamide) ± sequential paclitaxel 
EC (epirubicin/cyclophosphamide) 
TAC (docetaxel/doxorubicin/cyclophosphamide) 
A CMF (doxorubicin followed by cyclophosphamide/methotrexate/fluorouracil) 
E CMF (epirubicin followed by cyclophosphamide/methotrexate/fluorouracil) 
CMF (cyclophosphamide/methotrexate/fluorouracil) 
AC x 4 (doxorubicin/cyclophosphamide) + sequential paclitaxel x 4,every 2 weekly 
regimen with filgrastim support 
A T C (doxorubicin followed by paclitaxel followed by cyclophosphamide) every 2 
weekly regimen with filgrastim support 
FEC T (fluorouracil/epirubicin/cyclophosphamide followed by docetaxel) 
 
 Neoadjuvant Therapy 
The use of neoadjuvant or induction chemotherapy was first reported in the 1970s . Perez  
and colleagues reported their results of a pilot study by the Southeastern Cancer Study 
Group in 1979. This small study included 14 patients (five patients had inflammatory 
breast cancer and five had recurrences after mastectomy). All patients were treated with 
5-flurouracil, Adriamycin (doxorubicin), and cyclophosphamide (FAC) for two courses, 
followed by local therapy or radiation concurrently with cyclophosphamide and 5-
fluorouracil (CF). In the Perez group’s study, all patients received an additional eight 
courses of FAC. All but three of the patients had complete regression of their tumors 
following radiation therapy. The primary tumor showed partial regression (50% to 75%) 
in 65% of the patients after the first two courses of FAC.However all the trials concluded 
that induction chemotherapy was feasible but did not show any significant survival 
benefit . 
Given the absence of any difference in outcome for patients treated with neoadjuvant 
versus adjuvant chemotherapy, the decision to use preoperative versus postoperative 
chemotherapy must be based on other factors. Factors in favor of preoperative 
chemotherapy include the following:  
(1) patients initially presenting with tumors that historically required mastectomy can 
potentially be down-staged to allow for breast-conservation treatment; 
 (2) larger tumors that require a cosmetically unsatisfactory lumpectomy at presentation 
can be down-staged to allow a more cosmetically favorable lumpectomy;  
 (3) the response of individual patients to systemic chemotherapy can be assessed in vivo; 
 (4) research can be facilitated, for example, by evaluating tissue specimens before and 
after treatment, to rapidly assess new chemotherapeutic, hormonal, or biologic agents; & 
(5) the pathologic response to neoadjuvant chemotherapy is a strong prognostic factor for 
outcome. 
The argument in favor of primary surgery, if possible, with adjuvant systemic therapy is 
the more accurate pathologic staging, both of the primary tumor as well as the axillary 
lymph nodes, with the valuable prognostic information acquired for prognosis and 
guidance of adjuvant therapy. 
Numerous studies have demonstrated high rates of down-staging to breast-conservation 
treatment with the use of neoadjuvant chemotherapy. Although most studies have used 
doxorubicin- or epirubicin-containing regimens, studies have also begun to evaluate the 
role of taxane chemotherapy. After neoadjuvant chemotherapy, down-staging of the 
tumor sufficient to allow breast-conservation treatment has been reported in 22% to 90% 
of patients. For those patients with sufficient down-staging to permit breast-conservation 
surgery, definitive breast irradiation is also indicated and is delivered in a manner similar 
to that for patients not treated with neoadjuvant chemotherapy.  
Because physical examination and mammography do not adequately predict the 
pathologic response to neoadjuvant chemotherapy, alternative imaging methods have 
been developed to attempt to more accurately predict a pathologic response and to 
improve breast-conservation rates. MRI is one promising modality  and appears to 
correlate well with pathologic response. 
 Hormone therapy likely has a role to play as a neoadjuvant therapy, particularly when 
the diagnostic biopsy results confirm hormone receptor expression. The addition of 
endocrine therapy to chemotherapy appears to improve outcome for patients with locally 
advanced breast cancerThe role of postmastectomy radiation treatment after neoadjuvant 
chemotherapy is in evolution. The ASCO guidelines recommend that, in general, 
postmastectomy radiation treatment is indicated after neoadjuvant systemic therapy, 
although the guidelines recognize that there may be exceptions to this recommendation. 
The rationale for recommending postmastectomy radiation treatment is the significant 
down-staging associated with neoadjuvant chemotherapy, for both the primary tumor and 
axillary lymph nodes, and the fact that most patients who require mastectomy have 
presented initially with locally advanced tumors (T3 or T4 lesions) or four or more 
pathologically positive axillary lymph nodes. For postmastectomy radiation treatment 
after neoadjuvant chemotherapy followed by mastectomy, unresolved issues at this time 
include which patient and tumor factors (clinical and pathologic) should be used to select 
those patients who require treatment and the optimal technical radiation therapy fields, 
including which regional lymph nodes, if any, should be treated. 
Breast Conservation in the Setting of Multimodal Therapy 
 
The concept of breast conservation in patients with LABC was initially practiced to spare 
patients surgery who already had an extremely poor prognosis. Initial studies with 
radiation therapy alone accomplished breast conservation, but at the expense of a high 
rate of local-regional failure and distant relapse. Even studies of multimodal therapy in 
which only radiation was used as local therapy have had local-regional failure rates as 
high as 30% to 50%. The ability to reduce local failures by combining surgery and 
radiation therapy makes breast conservation treatment more appealing. Because induction 
chemotherapy may result in significant reductions in the size of the primary tumor, 
many patients with LABC would be candidates for breast conservation with a 
combination of surgery and radiation therapy. 
In 1990, Bonadonna et al” first reported the use of induction chemotherapy to downstage 
primary tumors and allow subsequent breast saving surgery. The criterion for breast-
saving surgery was a reduction in the tumor size to less than 3 cm. The group was able to 
avoid mastectomy for 127 (81%) of the 157 patients who had a surgical procedure.The 
treatment regimen consisted of three to four cycles of chemotherapy (CMF, FAC, or FEC 
[5-fluorouracil, epirubicin, cyclophosphamide]),followed by surgery and postoperative 
radiation therapy. Only116 women received postoperative adjuvant chemotherapy. 
Complete responses were seen after chemotherapy in 27 women, although 
histopathologic CR occurred in only nine. Up to 60% of the patients had at least a partial 
response to the induction chemotherapy. Among the first 83 patients who underwent 
surgery with at least 12 months of followup, 
the disease recurred in 13. Only one of the 75 women treated with breast conservation 
surgery experienced a local recurrence during this period. One patient treated with 
mastectomy had a local recurrence, and the remaining 11 patients developed distant 
metastases. 
Targeted therapy – recent advances  
Advances in molecular biology are reaching therapeutic application on several fronts. 
One example is the targeting of the HER-2 tyrosine kinase receptor. Trastuzumab 
(Herceptin, Genentech, San Francisco) is a humanized monoclonal antibody that binds to 
HER-2 with great affinity, resulting in growth arrest of HER-2 overexpressing cancer 
cells. The addition of trastuzumab to AC and paclitaxel improves time to progression, 
response rates, and overall survival for patients with advanced breast cancer 
overexpressing HER-2. Monoclonal antibodies are large molecules and are likely to be 
more effective in the adjuvant setting. Randomized trials that integrate trastuzumab in 
combination with chemotherapy are under way. 
 
 
Inoperable tumours 
 
• Patients with stage IIIB or IIIC disease, including those with inflammatory breast 
cancer and those with isolated ipsilateral internal mammary or supraclavicular 
lymph-node involvement, should be treated with primary anthracycline-based 
chemotherapy. • Acceptable chemotherapy regimens are FAC, CAF, CEF or FEC. 
Taxanes are under intense investigation. 
Inoperable LABC
Preoperative chemotherapy
Response No response
Total mastectomy 
with surgical 
axillary staging
RT to chest wall and 
supraclavicular LNs
and internal mammary 
nodes if involved +/-
delayed breast 
reconstruction
Lumpectomy with 
axillary staging 
RT to breast, 
supraclavicular
LNs & internal 
mammary if 
involved
Consider 
additional 
chemotherapy 
+/- pre op RT
response No 
response
As above individualise
Additional chemotherapy + hormone therapy 
if ER+/unknown  
NON-TRASTUZUMAB COMBINATIONS 
 
FAC chemotherapy : 
5-Fluorouracil 500 mg/m IV days 1 & 8 or days 1 & 4 
Doxorubicin 50 mg/m IV day 1 (or by 72 h continuous infusion) 
Cyclophosphamide 500 mg/m IV day 1 Cycled every 21 days for 6 cycles. 
 
CAF chemotherapy 
Cyclophosphamide 100 mg/m PO days 1-14 
Doxorubicin 30 mg/m IV days 1 & 8 
5-Fluorouracil 500 mg/m IV days 1 & 8 Cycled every 28 days for 6 cycles. 
 
AC chemotherapy 
Doxorubicin 60 mg/m IV day 1 
Cyclophosphamide 600 mg/m IV day 1 
Cycled every 21 days for 4 cycles. 
 
FEC chemotherapy 
Cyclophosphamide 75 mg/m PO days 1-14 
Epirubicin 60 mg/m IV days 1 & 8 
5-Fluorouracil 500 mg/m IV days 1 & 8  
With cotrimoxazole support.Cycled every 28 days for 6 cycles. 
 
AC followed by paclitaxel chemotherapy 
Doxorubicin 60 mg/m IV day 1 
Cyclophosphamide 600 mg/m IV day 1 Cycled every 21 days for 4 cycles.Followed by 
Paclitaxel 175-225 mg/m by 3 h IV infusion day 1 Cycled every 21 days for 4 cycles. OR 
Paclitaxel 80 mg/m by 1 h IV infusion weekly for 12 weeks. 
 
EC chemotherapy 
Epirubicin 100 mg/m IV day 1 
Cyclophosphamide 830 mg/m IV day 1 Cycled every 21 days for 8 cycles. 
 
TAC chemotherapy 
Docetaxel 75 mg/m IV day 1 
Doxorubicin 50 mg/m IV day 1 
Cyclophosphamide 500 mg/m IV day 1 Cycled every 21 days for 6 cycles. 
(All cycles are with filgrastim support). 
 
A followed by CMF chemotherapy 
Doxorubicin 75 mg/m IV day 1 Cycled every 21 days for 4 cycles. 
Followed by Cyclophosphamide 600 mg/m IV day 1 
Methotrexate 40 mg/m IV day 1 
5-Fluorouracil 600 mg/m IV day 1 Cycled every 21 days for 8 cycles. 
 
E followed by CMF chemotherapy 
Epirubicin 100 mg/m IV day 1 Cycled every 21 days for 4 cycles. 
Followed by Cyclophosphamide 100 mg/m PO days 1-14 
Methotrexate 40 mg/m IV days 1 & 8 
5-Fluorouracil 600 mg/m IV days 1 & 8 Cycled every 28 days for 4 cycles.OR 
Cyclophosphamide 750 mg/m IV day 1 
Methotrexate 50 mg/m IV day 1 
5-Fluorouracil 600 mg/m IV day 1 Cycled every 21 days for 4 cycles. 
 
CMF chemotherapy 
Cyclophosphamide 100 mg/m PO days 1-14 
Methotrexate 40 mg/m IV days 1 & 8 
5-Fluorouracil 600 mg/m IV days 1 & 8 Cycled every 28 days for 6 cycles. 
 
Dose-dense AC followed by paclitaxel chemotherapy 
Doxorubicin 60 mg/m IV day 1 
Cyclophosphamide 600 mg/m IV day 1 Cycled every 14 days for 4 cycles. 
Followed by Paclitaxel 175 mg/m by 3 h IV infusion day 1 Cycled every 14 days for 4 
cycles.(All cycles are with filgrastim support). 
 
Dose-dense A-T-C chemotherapy 
Doxorubicin 60 mg/m IV day 1 Cycled every 14 days for 4 cycles. 
Followed by Paclitaxel 175 mg/m by 3 h IV day 1 Cycled every 14 days for 4 cycles. 
Followed by Cyclophosphamide 600 mg/m IV day 1 Cycled every 14 days for 4 cycles. 
(All cycles are with filgrastim support). 
 
FEC followed by docetaxel chemotherapy 
5-Fluorouracil 500 mg/m IV day 1 
Epirubicin 100 mg/m IV day 1 
Cyclophosphamide 500 mg/m day 1 Cycled every 21 days for 3 cycles. 
Followed by Docetaxel 100 mg/m day 1 Cycled every 21 days for 3 cycles. 
TRASTUZUMAB CONTAINING COMBINATIONS 
AC followed by T chemotherapy with Trastuzumab 
Doxorubicin 60 mg/m IV day 1 
Cyclophosphamide 600 mg/m IV day 1 Cycled every 21 days for 4 cycles. 
Followed by Paclitaxel 175 mg/m by 3 h IV day 1 Cycled every 21 days for 4 cycles OR 
Paclitaxel 80 mg/m by 1 h IV weekly for 12 wks With Trastuzumab 4 mg/kg IV with first 
dose of paclitaxel Followed by Trastuzumab 2 mg/kg IV weekly to complete 1 year of 
treatment. As an alternative, trastuzumab 6 mg/kg IV every 3 wk may be used following 
the completion of paclitaxel, and given to complete 1year of trastuzumab treatment. 
Cardiac monitoring at baseline, 3, 6, and 9 months. 
 
Docetaxel + trastuzumab followed by FEC 
Docetaxel 100 mg/m by 1 h IV day 1 Cycled every 21 days for 3 cycles With 
Trastuzumab 4 mg/kg IV with first dose of docetaxel day 1 Followed by 
Trastuzumab 2 mg/kg IV weekly to complete 9 weeks of trastuzumab.Followed by 
5-Fluorouracil 600 mg/m IV day 1 
Epirubicin 60 mg/m day 1 
Cyclophosphamide 600 mg/m day 1 Cycled every 21 days for 3 cycles 
Cardiac monitoring at baseline, after last FEC cycle, at 12 and 36 months after 
chemotherapy. 
 
TCH (docetaxel, carboplatin, trastuzumab) 
Docetaxel 75 mg/m IV day 1 Followed by 
Carboplatin AUC 6 IV day 1 Cycled every 21 days for 6 cycles With 
Trastuzumab 4 mg/kg week 1 Followed by 
Trastuzumab 2 mg/kg for 17 weeks Followed by 
Trastuzumab 6 mg/kg IV every 3 weeks to complete 1 year of trastuzumab therapy 
Cardiac monitoring at baseline, 3, 6, and 9 months. 
 
AC followed by docetaxel with trastuzumab 
Doxorubicin 60 mg/m IV day 1 
Cyclophosphamide 600 mg/m day 1 Cycled every 21 days for 4 cycles Followed by 
Docetaxel 100 mg/m Cycled every 21 days for 4 cycles With 
Trastuzumab 4 mg/kg IV week one Followed by 
Trastuzumab 2 mg/kg IV weekly for 11 weeks Followed by 
Trastuzumab 6 mg/kg every 21 days to complete 1 y of trastuzumab therapy 
Cardiac monitoring at baseline, 3, 6, and 9 months. 
 
Neoadjuvant T followed by FEC chemotherapy with trastuzumab 
Trastuzumab 4 mg/kg IV for one dose beginning just prior to first dose of paclitaxel 
Followed by 
Trastuzumab 2 mg/kg IV weekly for 23 wks 
Paclitaxel 225 mg/m by 24 h IV infusion every 21 days for 4 cycles Followed by 
5-Fluorouracil 500 mg/m on days 1 and 4 
Epirubicin 75 mg/m IV on day 1 
Cyclophosphamide 500 mg/m on day 1 Cycled every 21 days for 4 cycles 
Systemic therapy: hormonal therapy 
 
Operable and inoperable tumours 
 
• Tamoxifen for 5 years should be recommended to pre-and postmenopausal women 
whose tumours are hormone responsive. 
Schinzinger was the first person to propose that oophorectomy might be of benefit in 
breast cancer based on the following observations : 
• Post menopausal breast atrophies. 
• More virulent tumor growth in premenopausal  women. 
The first reported series of surgical oophorectomy for breast cancer was reported by 
Thomas Beatson (1896).The report postulated the following effects of oopherectomy 
• Significant tumor regression by castration 
• Better sense of well being 
• Regression of cutaneous metastasis 
• Best above age of 40  
• No effect on osseous metastatsis 
Following Beatson's original report, oophorectomy became widely practiced but then was 
largely abandoned after only 10 years. The reasons why the procedure was abandoned are 
(a) the recognition that oophorectomy was not a curative procedure, as was originally 
thought by Beatson;  
(b) the lack of a sound therapeutic rationale; and 
 (c) the risks of intraabdominal surgery in the early twentieth century. 
It was not until the 1940s, when Charles Huggins described the hormonal responsiveness 
of prostatic cancer, that an interest in the hormonal treatment of breast cancer was 
resurrected . 
  The various modalities of endocrine manipulation available in the management of 
advanced breast cancer include : 
 Selective Estrogen Receptor Modulators: 1.Tamoxifen 
                                                                  2.Torimefen  
Androgens : Fluoxymesterone 
Progestins : Megestrol acetate 
   Medroxyprogesterone acetate 
High dose Estrogens 
 Aromatase inhibitors:1st generation: Aminoglutethemide 
                    2nd generation: Formestane (Type I) , Fadrazole 
  3rd generation: Exemestane (Type I) , Anastrazole ,                                                     
Letrozole,  Vorozole 
Steroidal Antiestrogens: Fulvestrant 
LHRH agonists : Leuprolide,   Goserelin 
Gland ablation : surgical (open/laparoscopic) ; chemical ;  radiation 
• Ovary ;  Pituitary ; Adrenals 
 
 
 
SELECTIVE ESTROGEN RECEPTOR MODULATORS : 
The SERMs are chemically diverse compounds that lack the steroid structure of estrogens 
but possess a tertiary structure that allows them to bind to the estrogen receptor. 
Examples:  Tamoxifen ; Raloxifen ; Tormifen 
The Selective modulation explained by: 
o Differential estrogen-receptor expression in a given target tissue 
o Differential estrogen-receptor conformation on ligand binding  
o Differential expression and binding to the estrogen receptor of coregulator 
proteins 
Tamoxifen 
Chemically a triphenylethylene.the trans isomer of which is used as a citrate salt. 
Mechanism Of Action: Competitive binding to the estrogen receptor resulting in 
reduction of transcription of estrogen regulated genes. 
Dimethylaminoethoxy side chain and the trans configuration are crucial for the 
antiestrogenic activity of tamoxifen 
The net result is a block in the G1 phase of the cell cycle and a slowing of cell 
proliferation.Tamoxifen is thus, a cytostatic drug. 
Binding and inactivation of estrogen receptor in cancerous cell : Predominant mode of 
action 
Other postulated mechanisms: 
Initiation of apoptosis in malignant cells 
Reduction of serum IGF-1 and increase in IGF-1 binding proteins are another potential 
mechanism of action. 
 
 Other actions: 
Increased sex hormone binding globulin ( ? Reduced estrogen bioavailability) 
Increased TGF β ( ? Increased pulm fibrosis / breast fibrosis if used concurrently with 
RT) 
Selective activation / inactivation of corepessors and coactivators responsible for 
selective agonist / antagonist activity 
Ancillary benefits of Tamoxifen 
Cardiovascular: 
Fewer non cancer related deaths due to cardiovascular events. 
Fewer hospitalizations for cardiac events 
Serum LDL / cholesterol reduced. 
Skeletal: 
Significant reduction in incidence of fractures of weight bearing bones. 
Estrogen agonist action on BMD 
Prevention of contralateral breast cancer 
Toxicity 
Menopausal symptoms:50% - 60% ( N.B. 40% - 50% in placebo) 
          MC in premenopausal 
           Vaginal dryness and discharge may occur in excess. 
Depression: 
Maybe seen in as high as 10% of patients. 
But no randomized comparisons available. 
Ocular toxicity: 
Keratopathy 
Thromboembolism:Severe thromboembolism seen in ~ 1% patients in the preventive 
setting.The risk is up to 10 times that experienced by healthy women.This complication is 
more common in elderly patients with metastatic breast cancer and who are receiving 
CCT 
Carcinogenesis:There is increased risk of endometrial cancers (hazard rate of 1.7 per 
1000 – NSABP B 14 data)but mostly low grade & stage I tumors. 
Other tumors: Hepatomas & Clear cell sarcomas of ovary 
Contraindications to Tamoxifen Treatment : 
Absolute: Retinal macular edema or degeneration 
History of benign or malignant liver tumor secondary to oral contraceptives 
Pregnancy 
Other hormonal therapy (estrogens, oral contraceptives) 
Relative: History of thrombophlebitis, particularly hormone related 
History of depression, particularly hormone related 
Cataract 
Drugs: Chlorpromazine, chloroquine, thioridazine, amiodarone, other 
Severe vasomotor symptoms 
Polycystic ovaries 
Radiation oophorectomy 
The first series on the effectiveness of radiation oopherectomy was reported by Foveau 
de Courmelles in 1922.The considerations in advocating Radiation oophorectomy 
include:1.  Non invasive and cheap procedure. 
             2.Low dose carries little additional morbidity. 
             3.However takes about 2 – 3 months for effect to appear. 
             4.For such reason best avoided when prompt relief is needed. 
             5.Also best reserved for the patient with slow progression of disease. 
Technique:   Position: Supine 
Field selection: Parallel opposing two field technique 
Energy : Co60 or 6 MV LINAC 
Dose Schedules:  
In a younger women 10 – 12 Gy in 5 -6 divided fractions is preferred. 
In older women shorter course of radiation can give equivalent ovarian ablation. 
Field borders: 
The volume of interest is the entire true pelvis 
10 x 15 cm field is opened. 
Lower border is placed just below the superior border of pubic symphysis. 
Recommendations for adjuvant hormonal therapy :                         
Following completion of chemotherapy, pre- or postmenopausal patients with LABC and 
hormone-responsive tumours should receive adjuvant tamoxifen therapy, 20 mg/d, for 5 
years  Tamoxifen should be started after completion of chemotherapy. The aromatase 
inhibitor, anastrozole, has been compared with tamoxifen in postmenopausal women with 
early breast cancer following surgery. The early results of that study showed that , 
compared with tamoxifen, anastrozole was associated with improved DFS and had fewer 
side effects. The role of aromatase inhibitors as adjuvant therapy in breast cancer is 
evolving. The role of luteinizing hormone-releasing hormone agonists in premenopausal 
patients is evolving as new data emerge . Patients who are not candidates for any 
chemotherapy can be managed with hormonal treatment and then receive locoregional 
management. 
NCCN Guidelines for hormonal  therapy : 
 
 
 
 
Locoregional management 
 
Operable tumours 
 
• Patients with stage IIIA disease should receive both modified radical mastectomy 
(MRM) and locoregional radiotherapy if feasible. They may be managed with MRM 
followed by chemotherapy and locoregional radiotherapy, or chemotherapy first 
followed by MRM and locoregional radiotherapy. Breast-conserving surgery is 
currently not a standard approach.  
MRM (mastectomy plus a level 1 and level 2 axillary dissection) remains the standard 
surgical treatment for operable locally advanced disease. The second half of the 20th 
century witnessed increasing disillusionment with radical and mutilating forms of surgery 
for breast cancer. As a result the trend towards breast conservation has increased since 
the mid-1960s, although a number of centres had adopted this approach since before the 
Second World War. Again there are a number of different descriptions relating to breast 
conservation which has caused confusion. Tumourectomy, lumpectomy, tylectomy, 
segmental mastectomy, and quadrantectomy are all synonymous with a therapeutic 
procedure in which the primary tumour is removed and the breast is preserved. 
Unfortunately, these terms are not precisely defined, although they imply the removal of 
varying amounts of normal breast tissue in association with a primary tumour. The terms 
&lsquo;lumpectomy&rsquo, &lsquo;tumourectomy&rsquo and lsquo&tylectomy&rsquo; 
imply removal of the tumour with a minimal or no margin of normal breast tissue around 
it. Segmental mastectomy implies excision of the tumour with a rim of associated normal 
breast tissue. However, this term is also somewhat misleading as it implies that the breast 
is anatomically a segmental organ and that tumours occur in a localized segment. This is 
clearly not the case. The term lsquo;quadrantectomy&rsquo; denotes removal of a breast 
quadrant, and implies wider excision of normal breast tissue than segmental mastectomy. 
In practice, however, there is little distinction between these terms and although a number 
of authorities have recommended the adoption of a uniform nomenclature, none has 
found universal favour. 
Once the questions regarding definition of terms and nomenclature have been addressed 
the simple, yet fundamentally important question which remains is whether breast 
conservation provides results as reliable in the treatment of breast cancer as total  
Mastectomy. 
mastectomy. Furthermore, is there an additional benefit in terms of cosmetic and 
emotional adjustment? Finally, if breast conservation is justified, in which patients is this 
appropriate? 
 
 
 
 
 
The role of BCS is unclear and the subject of research. Previous studies demonstrating 
equivalence of BCS to mastectomy were performed in patients with stage I and II disease  
see guideline  In the trials that compared preoperative chemotherapy with chemotherapy 
administered postoperatively, the proportion of women with tumours greater than 5 cm in 
diameter ranged from 5% to 27%. Patients with operable stage III disease who desire to 
preserve their breast should be made aware that BCS is currently not a standard approach 
and is generally not recommended. 
 
Colour plate 1 : standard incision for MRM 
 
Colour plate 2 : Specimen of MRM 
 Anatomical structures removed in various types of mastectomy 
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Sub-cutaneous  X           
 
Total (simple) X  X X         
 
Modified simple) X  X X X        
 
Total with axillary 
dissection. 
X  X X X X       
 
Auchincoloss MRM X  X X X X X      
 
Scanlon MRM X  X X X X X X     
 
Patey MRM X  X X X X X X X    
 
Halstead RM X  X X X X X X X X   
 
Urban ERM X  X X X X X X X X X  
 
Dahl-Iversen ERM X  X X X X X X X X X X 
 
Super-radical 
(Wangensteen) 
X  X X X     X X X X X X X X 
 
 
 Colour plate 3 : Breast reconstruction therapy 
T he contraindications to BCS were determined in 1991 by a panel of representatives 
from the American College of Surgeons, the American College of Radiology, the College 
of American Pathologists, and the Society of Surgical Oncology:  
Absolute contraindications to breast-conserving surgery:  
1.Pregnancy: first and second trimester 
2.Multicentricity: two or more gross tumors in separate quadrants 
3.Diffuse undetermined or malignant-appearing microcalcifications 
4.History of previous irradiation to the breast region viz mantle RT 
Relative contraindications to breast-conserving surgery 
1.Large tumor/breast ratio with respect to acceptable cosmetic results 
2.Large breast size 
3.Tumor location beneath the nipple 
4.History of collagen vascular (connective tissue) disease 
A tumor located beneath the nipple might not be considered a contraindicationto breast-
conserving surgery if the patient understands the anticipated deficit and desires the 
procedure. Extremely large breast size is also not a contraindication to breast-conserving 
surgery if radiation therapy can assure dose homogeneity. 
 
In terms of management of the breast the simplest approach would be to remove the 
tumour itself, preferably with a margin of normal tissue around it. In theory the more 
limited procedures of tumourectomy or lumpectomy are likely to be followed by a good 
cosmetic result but are more likely to be followed by local recurrence because of the 
likelihood of failure to excise the tumour completely. More extensive forms of 
conservative surgery such as quadrantectomy are more likely to provide good tumour 
control but are more liable to be followed by a less satisfactory cosmetic result because of 
the amount of breast tissue excised. 
Nearly all of the series evaluating Skin Sparing Mastectomy comprise Stage 0, I, and II 
breast carcinomas. Some have also included a few Stage III tumors, which were clinically 
thought to represent earlier-stage lesions preoperatively .Foster et al evaluated outcomes 
for SSM with immediate reconstruction in patients with locally advanced disease, 
specifically Stages IIB and III. With a median follow-up of 49.2 months, the rate of local 
recurrence was 4%, which is comparable to the reported overall local recurrence rates in 
the literature. They concluded that this procedure is safe, effective, and has a low 
morbidity on women with locally advanced breast carcinoma SSM can be performed for 
noninvasive or invasive breast cancer. Simmons et al reported that among NSSM 
patients, 62% had modified radical mastectomies, 37% had total mastectomies, and fewer 
than 2% had radical mastectomies; and that among SSM patients, 44% had modified 
radical mastectomies, 56% had total mastectomies, and none had radical mastectomies . 
Postoperative adjuvant chemotherapy or radiation therapy is indicated based upon the 
size of the primary tumor and the number of positive axillary lymph nodes. A recent 
study showed that 49% of both NSSM and SSM patients received postoperative adjuvant 
chemotherapy.Postoperative radiation therapy is typically given because of a tumor size 
greater than 5 cm or because of numerous axillary lymph nodes with metastatic disease. 
In one series, it was performed in 3% of SSM and in 12%of NSSM (P = NS). Although 
there is some cosmetic disadvantage to postoperative radiation therapy in patients who 
have tissue-expander reconstruction, patients with autologous reconstruction often 
maintain an excellent cosmetic outcome. If it is suspected before reconstruction that 
postoperative radiation will be indicated, one option is to create the reconstructed 
breast slightly larger than the contralateral breast, which often results in a more 
symmetrical long-term outcome after radiation. 
Locoregional radiotherapy should be delivered to the chest wall and to the  
supraclavicular and axillary nodes. The role of internal mammary irradiation is not 
clear. 
 
 When locoregional radiotherapy is delivered following MRM for locally advanced 
disease, radiation should be delivered to the chest wall,supraclavicular and axillary nodes. 
Whether treatment to the internal mammary nodes is required is unclear. In many of the 
studies reviewed for this guideline, the internal mammary nodes were irradiated. 
However, there are no studies that examined the impact of such radiotherapy. It is not 
unreasonable to include radiotherapy to the internal mammary nodal region, provided that 
this can be done without treating an excessive amount of heart or lung tissue. 
Locoregional radiotherapy has been associated with a modest increase in late non-breast-
cancer deaths of cardiac or vascular origin. The recommended dose of radiation is 50 Gy 
in 25 fractions or equivalent. 
 
Inoperable tumours  
 
• Patients with stage IIIB disease who respond to chemotherapy should receive 
surgery plus locoregional radiotherapy. 
• The locoregional management of patients with stage IIIC disease who respond to 
chemotherapy is unclear and should be individualized. 
• Patients whose disease remains inoperable following chemotherapy should receive 
locoregional radiotherapy and subsequent surgery if feasible. 
The locoregional management of patients with stage IIIC disease who respond to 
chemotherapy is unclear. In the absence of evidence on this subgroup of patients, it is 
reasonable that they receive locoregional radiotherapy (including nodal irradiation). The 
role of completion mastectomy should be individualized and based on such factors as 
response to chemotherapy and radiotherapy,absence of metastases on re-staging 
examinations and patient fitness. 
 
Patients who are treated primarily with radiotherapy should be given tumouricidal doses 
to areas of bulk disease (60–66 Gy in 30 to 33 fractions or equivalent). Higher doses of 
radiation (70 Gy in 35 fractions by external beam or brachytherapy) to areas of bulk 
disease may be considered for patients if surgery is felt not to be an option and if 
tolerance of critical organs permits. Two case series have reported a dose-response 
relation with higher doses of radiation that resulted in decreased rates of local recurrence 
For the patient who has a partial or complete response to chemotherapy and whose lesion 
is converted to an operable state, the next maneuver is typically mastectomy to debulk 
gross disease, to facilitate local-regional control, and to allow for the pathologic 
assessment of response. For patients with a complete or partial response, the optimal 
chemotherapy to use after local-regional treatment is uncertain. Specifically, it is not 
clear whether to continue the same chemotherapy as before after local-regional treatment 
or whether a cross-resistant chemotherapeutic regimen is indicated. The ASCO 
guidelines recommend postmastectomy radiation treatment, in general, for those patients 
who require a mastectomy 
For the patient whose tumor remains inoperable after first-line systemic chemotherapy, 
the options are to proceed with second-line chemotherapy or to deliver preoperative 
radiation treatment. One major goal of treatment is to attempt to convert the lesion from 
an inoperable to an operable state, because patients without local-regional control have 
substantially diminished quality of life.  
According to the St. Gallen conference,node-negative patients with a low risk for 
recurrence should not receive adjuvant chemotherapy. These include  
Node-negative infiltrating ductal or lobular carcinoma 
Tumor size less than 1 cm 
Well differentiated (histologic grade 1) 
ER or PR positive 
Age of 35 or more 
size is less than 3 cm 
Pure mucinous, tubular, papillary, and adenocystic carcinoma if the tumor 
Contraindications to therapy (toxicity) 
Concurrent incurable, terminal illness 
Severe cardiovascular, hepatic, or renal disease 
Severe bone marrow deficiency 
Severe immunodeficiency 
Mental illness 
Locally advanced breast cancer and sentinel node biopsy 
Clearly, the status of the axillary lymph nodes still has an important prognostic role in 
LABC treated with neoadjuvant protocols. The driving question now is when to stage the 
axilla. Should the axilla be staged prior to and/or following neoadjuvant therapy? 
  Feasibility of sentinel node biopsy for LABC 
Sentinel node biopsy has been extensively studied in early breast cancer and has been 
found to have an accuracy from 92% to 100% with successful identification of 90–100%  
However, limited experience in LABC is only now beginning to emerge and very little 
experience with SLNB after neoadjuvant therapy has been reported. Estimates of the 
accuracy and false negative rates (FNRs) of SLNB based on published tumor size suggest 
that for primary lesions greater than 3.0 cm, the accuracy should be as high as 96% . 
Other groups, have directly evaluated the accuracy of SNB in LABC prior to any 
treatment. Bedrosian et al. evaluated 104 patients of whom 87 had T2 and 17 had T3 
lesions and a clinically negative axillary exam. They were successful in identifying the 
SN in 99% of the cases with a FNR of only 3%. This would suggest that SLNB before 
neoadjuvant therapy is highly accurate for patients with large tumors.  
 Sentinel node biopsy following neoadjuvant treatment of LABC 
 The experience with neoadjuvant chemotherapy and SLNB is limited but has been 
successful in several trials and can be considered on a case-by-case basis at 
institutions that have had abundant experience with SLNB and neoadjuvant 
chemotherapy. Clearly the role of SLNB in LABC and neoadjuvant therapy has yet to be 
defined, but certainly this powerful diagnostic tool will play a prominent role. 
 
 
 
 
Reconstructive surgery in LABC: 
The goal of reconstructive surgery for patients with locally advanced breast carcinoma 
can be to repair defects or to repair defects and to recreate the breast mound.In patients 
with LABC who need or elect to have standard mastectomy and who desire breast 
reconstruction to improve the cosmetic outcome,reconstruction is often delayed until 
completion of  both adjuvant chemotherapy and irradiation.As most locoregional 
recurrences are in the skin or subcutaneous tissue of chest wall,a flat post-mastectomy 
defect often makes irradiation technically easier than does a reconstructed breast 
mound,especially if the inclusion of the internal mammary nodal basin is 
necessary.However in selected patients with excellent response to induction 
chemotherapy or when palliative debulking surgeries are needed,the use of an autogenous 
flap to create a breast mound or provide skin coverage of the operative defect before 
radiotherapy is instituted if feasible. 
The use of a myocutaneous flap for breast reconstruction,either before or after 
irradiation,does not interfere with the resumption of chemotherapy or the ability to detect 
locoregional recurrence.Irradiation of the reconstructed breast mound flap does not 
impair the flap’s blood supply.Provided that the flap has an adequate vascularisation 
without evidence of significant fat necrosis,the irradiation itself does not alter the 
cosmetic result except for the anticipated skin tanning and slight fibrosis of the 
reconstructed breast mound . 
The  two tissue flaps that have been most frequently used for breast reconstruction are the 
lattissimus dorsi and rectus abdominis myocutaneous flaps.The advantages of the 
Latissimus dorsi flap include its reliable blood supply ant the relative rarity of donor site 
morbidity.The flap is also relatively thin and so matches the thickness of the native chest 
wall skin fairly closely and also provides excellent soft tissue coverage.The chief 
disadvantage of the Latissimus dorsi flap is its limited size;an implant is usually required 
if the patient desires a reconstructed reast mound. 
The Rectus abdominis myocutaneous flaps can be quite large and are most useful for 
defects too large to repair with a LD flap.The chief disadvantage is that they tend to be 
bulky and thus do not closely match the thickness of the native chest wall skin.The 
thickness of the flap can be an advantage,however if the defect is located directly over the 
central area of the chest wall;in this case the excess flap may be utilized to reconstruct a 
breast mound.  
The two main types of Rectus abdominis myocutaneous flaps are the transverse rectus 
abdominis myocutaneous flap(TRAM) and the vertical rectus abdominis myocutaneous 
flap(VRAM).The TRAM flap has a greater arc of rotation and a more symmetrical and 
easiliy concealed donor site than does the VRAM flap.The VRAM flap leaves a more 
noticeable donor scar but is easier to construct and has a more reliable blood supply. 
For major chest wall resections,the rectus abdominis flap is capable of covering a wide 
area from the clavicle to the costal margin and from the sternum to the midaxillary 
line.Because the flap is bulky,it provides sufficient chest wall stability even when upto 
five ribs or the entire sternum is resected,without the need for prosthetic mesh.Marlex,a 
nonabsorbable durable mesh can be used for flat surfaces of the chest wall.If the defect is 
large,a sandwich of  Marlex and methyl methacrylate can be formed to restore a more 
normal contour.If the mesh is covered by well vascularised tissue,the risk of infection and 
extrusion is usually low. 
Immediate breast reconstruction (IBR) is now recognized as an esthetically acceptable 
and oncologically safe treatment option for many early-stage breast cancer patients 
who undergo mastectomy. However, patients with locally advanced breast cancer 
(LABC) historically have been considered poor candidates for IBR for several 
reasons: (1) concerns regarding increased risk of local recurrence (LR) and possible 
delays in detecting LR; (2) concerns that prolonged recovery from extensive surgery 
would result in delays in postoperative chemotherapy ; (3) concern about a possibly 
higher risk of wound infections in patients who have received preoperative 
chemotherapy; and (4) concerns regarding the technical difficulties of irradiating the 
reconstructed breast. Despite these issues, IBR has been performed in many women 
with LABC, because of (1) strong patient preference, unclear preoperative assessment of 
extent of disease, or (3) need to provide soft tissue coverage for an extensive 
mastectomy defect. 
 
INFLAMMATORY BREAST CARCINOMA  
 
In 1814, Sir Charles Bell first recognized the clinical evolution of IBC when he wrote: "a 
purple color on the skin over the tumor accompanied by shooting pains, is a very 
unpropitious beginning.”Later in the nineteenth century, Klotz described ”mastitis 
carcinomatosa” as a variant of carcinoma of the breast characterized by its fulminant 
course.” In 1889, Bryant reported the association of dermal lymphatic invasion with 
the clinical characteristics of 1BC.’ The term inflammatory was coined by Lee and 
Tannenbaum in 1924.T heir paper was the first to describe in great detail the clinical 
characteristics of IBC in a series of 24 patients.Several other names have been used to 
describe this entity including carcinoma mastitoides, carcinoma e ysipeloides, lactation 
cancer, and malignant lymph~ngitisB.~e~tw een 1908 and 1911, the term acute 
carcinoma was used by several investigators, and Leitch, in 1909, introduced the french 
term “peau d’orange” in an English literature paper. Taylor and Meltzer subsequently 
described two clinical varieties of inflammatory breast cancer: 
(1) Primary inflammatory breast cancer, characterized by a sudden onset of the above 
symptoms in a breast which previously appears normal; 
(2) Secondary inflammatory breast cancer, defined by inflammatory symptoms and signs 
which appear in a breast with a previous mass, in the chest wall postmastectomy 
or in the contralateral breast . 
  
 Inflammatory breast cancer is a distinct clinical subtype of locally advanced breast 
cancer, with a particularly aggressive behavior and poor prognosis. Clinically, 
inflammatory breast cancer typically presents with the rapid onset of breast erythema, 
warmth, and edema, often without a discrete underlying mass. The swelling of the breast 
can be quite pronounced, producing significant tenderness.Although histologic proof of 
malignancy is critical prior to treatment of IBC, documenting dermal lymphatic 
permeation is not critical in establishing the diagnosis of IBC. 
 
 IBC is defined under the current American Joint Committee on Cancer (AJCC) manual 
for staging of cancer as T4d NO-2 stage III b, carcinoma of the breast. This corresponds 
to Haagensen’s stage D of the Columbia Clinical Classification. Bonnier et al. classified 
patients into three groups according to clinical and histopathological features  
Group A included patients with typical inflammatory breast cancer (diffuse enlargement 
of the breast, often no palpable tumour, redness and oedema of the skin).Ipsilateral 
enlargement of the axillary nodes was often detected and emboli of carcinoma cells in the 
subdermal lymphatics were often found. 
Group B included patients with occult inflammatory breast cancer, in which the presence 
of tumour emboli in dermal lymphatics was not associated with inflammatory 
symptoms and signs. 
Group C included patients with pseudo-inflammatory breast cancer. Symptoms were 
similar to those of groupA. However a tumour mass was more readily palpable 
and the sub-dermal lymphatics were never involved.Furthermore, the axillary nodes were 
rarely involved. 
Evaluation of IBC 
Evaluation of patients presenting with IBC must be multidisciplinary.This includes a 
thorough documentation of physical findings and extent of disease, including axillary and 
supraclavicular lymph node enlargement. Bilateral mammograms are performed to ensure 
that this is a unilateral process and as a baseline for future reference. Although core-
needle biopsy affords the most efficient proof of malignancy, we prefer an incisional 
biopsy including skin to determine dermal lymphatic involvement . Hormone receptor 
analysis, DNA content, and Sphase fraction are routinely perfornted. Metastatic work-up 
includes CT scans of the chest and upper abdomen, including liver and adrenalglands; 
bone scintigraphy; liver enzymes; and carcinoembryonic antigen determination.Bryant" 
attributed the inflammatory signs in this type of cancer to diffuse lymphatic blockage by 
cancer cells, but this finding is not specific for IBC. Inflammatory breast cancer exhibits 
all the usual microscopic features of infiltrating ductal carcinoma. IBCs are poorly 
differentiated and without evidence of glandular formation.  
  Neglected locally advanced breast cancer can develop secondary inflammatory 
characteristics, but should be distinguished from primary inflammatory carcinoma as 
these secondary inflammatory breast cancers may follow a more indolent course and can 
be treated as other locally advanced breast tumors.  
Three biological features make inflammatory breast cancer a unique clinical entity : 
(1) Rapidity of progression 
(2) High angiogenic and angioinvasive capability 
(3) Aggressive behaviour from inception. 
 van Golen et al. found that overexpression of RhoC GTPase and the lost in inflammatory 
breast cancer (LIBC) protein were highly correlated with an inflammatory breast cancer 
phenotype. These tumors are more likely to be high grade, aneuploid, and hormone-
receptor negative and have a high S-phase fraction and p53 mutations. Despite these 
differences in biologic characteristics, prognostic factors for inflammatory breast cancer 
are similar to those for locally advanced disease, with axillary lymph node involvement 
predicting poorer survival. Other negative prognostic factors for inflammatory carcinoma 
include negative ER status, extensive erythema of the breast, and p53 mutations.  
 Management of IBC 
The optimal treatment of inflammatory breast cancer requires careful coordination of 
multimodal therapy among medical, radiation, and surgical oncologists.Current treatment 
for inflammatory breast cancer centres upon neoadjuvant chemotherapy. The advent of 
neoadjuvant chemotherapy has greatly improved disease-free and overall survival for 
inflammatory breast cancer  Ueno et al., in their series of 178patients, report overall 
survival of 40% at 5 years and 33% at 10 years. Given that inflammatory breast cancer 
metastasises early, sub-clinical systemic disease is likely to exist, which may be 
controlled by neoadjuvant chemotherapy. The initial component of treatment hence 
should be induction chemotherapy with an anthracycline-based regimen or an 
anthracycline and taxane combination. Definitive local therapy can then be achieved with 
radiation therapy, mastectomy, or both. .  After local therapy, patients should receive 
further adjuvant chemotherapy, as the risk of relapse remains high, followed by adjuvant 
radiotherapy, if not previously given. 
 Role of surgery in IBC 
Early experience with surgery for inflammatory breast cancer was uniformly 
disappointing, with high rates of recurrence and poor overall survival. The role of surgery 
is now being re-evaluated due to the effectiveness of neoadjuvant chemotherapy, 
whichhas resulted in downstaging of disease with decreased tumour burden . This 
provides a greater opportunity for adequate surgical resection.Curcio et al.found that  a 
successful outcome for surgery for inflammatory breast cancer following neoadjuvant 
chemotherapy depended upon achieving negative excision margins. Lopez and Porter  
noted that consistently achieving tumour-free resection margins can be technically 
difficult in inflammatory breast cancer patients, and may require complex reconstructions 
with myocutaneous flaps and extensive cutaneous dissection. Breast conservation is 
rarely possible.  
 
 
Sentinel lymph node biopsy may also be unsuitable in the setting of inflammatory breast 
cancer due to the high level of nodal involvement found in this disease. Also since cancer 
infiltrates the dermis and lymphatics in inflammatory breast cancer, the underlying 
architecture may be disrupted to the extent that sentinel lymph node biopsy is not of 
value 
Relatively few women with inflammatory breast cancer have been offered reconstructive 
surgery following surgery . Concerns about reconstruction include delays to adjuvant 
treatment, difficulty in the detection of recurrence and increase in morbidity. Given the 
improved multimodality treatment of inflammatory breast cancer, reconstructive 
procedures should be offered as part of comprehensive therapy, as long as a positive 
margin at resection is not expected(Chin et al). The exact indications for surgery and the 
optimal operation, however, remain unclear. 
Radiotherapy was the mainstay of care for inflammatory breast cancer for many years, 
but the results were unimpressive. Radiotherapy alone has been shown to improve local 
control rates in treatment of inflammatory breast cancer, but to have no effect on survival  
Since the introduction of neoadjuvant chemotherapy, and the return of surgery, 
radiotherapy is now seen as an important part of a multimodality treatment approach, 
rather than treatment on its own. The importance of radiotherapy relates primarily to its 
function in loco-regional control. 
No substantial improvement in survival from hormone therapy for inflammatory breast 
cancer has been shown , which is not surprising given that patients with inflammatory 
breast cancers are more frequently oestrogen and progesterone receptor negative 
compared with other breast cancers. Nevertheless, if the tumour is oestrogen receptor 
positive it is currently advised that patients receive 5 years of treatment with either 
tamoxifen or aromatase inhibitors. 
Recent discoveries of the distinct biologic features that characterize inflammatory 
carcinoma can lead the way toward the development of new therapies. For instance, 
farnesyl transferase inhibitors have been shown to reverse the invasive phenotype of 
RhoC GTPase-overexpressing cell lines. Other possible therapeutic targets include 
mediators of angiogenesis such as vascular endothelial growth factor, basic fibroblast 
growth factor, and Flt-1, which are overexpressed in inflammatory breast cancers.  
 
Allocation of resources : 
 
The treatment of breast cancer requires an integrated,multidisciplinary approach using 
multiple resources in a focused, disease-oriented manner. Existing evidence-based 
guidelines outlining optimal approaches to the treatment of breast cancer have been 
defined and disseminated,but do consider the multiple deficits in infrastructure and the 
availability of therapies in limited-resource countries. Marked heterogeneity exists among 
countries and also between regions of the same country with regard to social, economic, 
and health system development.Therefore a uniform approach for all limited-resource 
countries is neither practical nor realistic. The BHGI has proposed a stepwise, systematic 
approach for building national or regional breast health treatment systems by stratifying 
health care resources into four levels—basic, limited,enhanced, and maximal—based on 
the contribution of incremental resources in improving clinical outcomes. 
Table. Treatment and Allocation of Resources: Locally Advanced Breast Cancer 
 
Local-regional Treatment Systemic Treatment (Adjuvant)Level of 
Resources Surgery Radiation Therapy Chemotherapy Endocrine 
Therapy 
Basic Modified radical 
mastectomy 
  Neoadjuvant AC, 
FAC, or classical 
CMFa 
Ovarian 
ablation  
 
Tamoxifen  
Limited   Postmastectomy 
irradiation of the chest 
wall and regional nodes 
    
Enhanced Breast-
conserving 
therapyb 
Breast-conserving 
whole-breast irradiation
Taxanes Aromatase 
inhibitors  
 
LH-RH 
agonists  
Maximal Reconstructive 
surgery 
  Growth factors  
Dose-dense 
chemotherapy  
  
aRequires blood chemistry profile and complete blood count (CBC) testing. 
bBreast-conserving therapy requires mammography and reporting of margin status. 
AC, doxorubicin and cyclophosphamide; CMF, cyclophosphamide, methotrexate, and 5-
fluorouracil; EC, epirubicin and cyclophosphamide; FAC, 5-fluorouracil, doxorubicin, 
and cyclophosphamide; LH-RH, luteinizing hormone releasing hormone. 
SURVEILLANCE/FOLLOW-UP 
 
Despite advances in the multidisciplinary approach in the management of locally 
advanced breast cancer that has improved the prognosis as well as the quality of life  
considerably ,the overall survival remains almost constant.That the prognosis is stage 
dependant has been well established. 
 
Interval history and physical exam every 4-6 months for 5 years, then every 12 months 
Mammogram every 12 months (and 6-12 months post-RT if breast conserved)  
Women on tamoxifen: annual gynecologic assessment every 12 months if uterus present 
Women on an aromatase inhibitor or who experience ovarian failure secondary to 
treatment should have monitoring of bone health 
Assess and encourage adherence to adjuvant hormonal therapy. 
Patient education on recurrence, morbidity of treatment ,psycho social aspects,prosthesis 
before ,during & at completion of treatment 
Breast self examination – monthly 
Haematology,Bioprofile,Imaging 
Assay   for tumour markers                             not recommended routinely            
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   Aims & objectives : 
1. To ascertain the incidence of LABC among the women presenting with breast cancer. 
2.To define the optimal treatment for women with stage III or locally advanced breast 
cancer (LABC). 
3.To ascertain the feasibility of the defined optimal treatment and to advocate it among 
patients with LABC. 
Period of study : May 2005 – October 2007 
Methods 
 
 We conducted a  review of the literature in the English-language  retrieved from internet 
and medical journals regarding the management of locally advanced breast cancer.Search 
terms used were “breast neoplasms,” “locally advanced breast cancer,” “stage III breast 
cancer,” “drug therapy,” “neo-adjuvant,” “primary systemic therapy,” “radiotherapy or 
irradiation,” “surgery,” “randomized trials” and “high-dose therapy.”  Additional data 
were identified by reviewing references in retrieved reports and by monitoring major 
conferences on breast cancer. The main outcomes considered are  locoregional control 
(defined as freedom from recurrence in the breast, chest wall or regional lymph nodes), 
disease-free survival (DFS; defined as survival free of breast cancer recurrence) and 
overall survival (OS). 
   Numerous setbacks encountered in the process of synthesizing the results of the studies 
from the review of the literature included : 
1.Majority of the studies were from the western population that differed vastly from the 
Indian scenario. 
2.The studies included different populations of patients with differing prognoses; for  
example, some studies included patients with inflammatory breast cancer whereas other 
studies did not. 
3.In studies evaluating systemic therapies, local therapy (surgery/radiotherapy) was often 
not standardized. 
 4.The TNM tumour-staging system changed, in that tumours associated with ipsilateral 
supraclavicular nodal involvement that were initially considered LABC were considered 
metastatic breast cancer between 1987 and 2002 and are now considered LABC again. 
5.The randomized trials that were available were old, had small patient numbers and used 
systemic therapy combinations that are often not used today. 
 6.The various recent advances available as of today could not be utilized in the study 
owing to patient’s socioeconomic ceiling.For example hormone receptor assay /her-2 neu 
assay /bone scan could not be advocated. 
7.Breast reconstruction / breast conservation could not be tried for the lack of 
infrastructure and patient compliance. 
Patients and methods 
Between May 2005 and October 2007, a total of  43 cases of carcinoma breast were 
admitted in our surgical unit in the Government Rajaji Hospital,Madurai.All of those 
admitted were staged according to the AJCC TNM  classification. Staging work-up 
consisted of a complete bloodcount (CBC), blood chemistry, chest X-ray,and 
ultrasonography of the liver.Either FNAC/ Trucut / incisional biopsy were used to 
confirm the diagnosis of carcinoma breast. 
Stage I, 
1, 2%
Stage III, 
29, 69%
Stage IV, 
8, 19%
Stage II, 
4, 10%
 
Figure : Carcinoma breast stage distribution in our study population. 
 Of the 43 patients, 
 one of them was of male sex ; 42 were of female sex.For all practical purposes only the 
42 female breast carcinoma were considered for the study. 
18 were right – sided & 24  left-sided, 
one of stage I ; four of stage II ; 29 of stage III ; 8 of stage IV. 
Of the 30 cases of LABC, (29 of III & 1 of II) 
one of them was inflammatory carcinoma 
18 were  post – menopausal & 12 were pre- menopausal. 
The HPE in all the cases were of infiltrating ductal carcinoma.Since ER status could not 
be ascertained,all of the cases were considered ER + for all practical purposes.  
 All of the cases of LABC except for the inflammatory carcinoma  underwent modified 
radical mastectomy,followed by adjuvant chemoradiation & Hormonal therapy .Adjuvant 
chemotherapy consisted of 6 cycles of CAF regimen.Adjuvant radiation included EBRT 
of 5000 Gy to the tumour bed & nodal basins.Receptor status could not be ascertained. 
So, the receptor status was considered positive for all practical purposes and adjuvant 
hormonal therapy in the form of tamoxifen 10 mg bd was instituted for a period of 5 
years. 
Conclusions : 
The incidence of LABC among the study population was approximately 69%.LABC 
forms the majority of  the cases of  breast cancer  at the time of initial presentation 
itself.The significance of this conclusion is that what cases are classified at a specific 
instance as LABC once belonged to the category of early breast cancer and subsequently 
evolved into LABC due to either  patient’s negligence or inappropriate intervention  or 
aggressive tumour biology.Thus as prevention is always better than cure it is 
recommended that the following measures can be adopted to address this problem : 
1.Health education regarding self breast examination 
2.screening mammography 
3.Identifiation of high risk population and specific management 
4.Surveillance when family history is positive for breast cancer. 
Metastatic work-up is mandatory. 
Hormone receptor assay may be useful in planning treatment  
For better management of patients with LABC, the following is recommended: 
• Early diagnosis of breast cancer is vital for better results of treatment. General 
education about early symptoms of the disease and access to medical facilities are 
important in diminishing breast cancer mortality in our country. 
• Cellular biological markers such as Her-2, P53, etc. should be evaluated as prognostic 
factors in prospective randomized studies. 
• Randomized trials are recommended for comparing new adjuvant regimens   
 Lack of treatment compliance and/or failure to provide standard-of-care treatment in 
high-risk breast cancer can lead to a higher incidence of metastatic cancer and mortality.  
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                                                    Abbreviations used  
LABC – Locally advanced breast carcinoma 
IBC – Inflammatory breast carcinoma 
MRM – Modified Radical Mastectomy 
SSM – Skin sparing mastectomy 
BCT – Breast conservation surgery 
NSSM – Non skin sparing mastectomy 
AJCC – American joint committee on cancer 
ASCO –American society of clinical oncology 
NCCN – National cancer comprehensive network 
BHGI – Breast health global initiative 
VRAM – Vertical rectus abdominis myocutaneous flap 
TRAM – Transverse rectus abdominis myocutaneous flap 
CBC – Complete blood count 
LR – Local recurrence 
CR – Complete response 
PR – Partial response 
IBR – Immediate breast reconstruction 
OS – Overall survival  
DFS – Disease free survival 
SLNB – Sentinel lymph node biopsy 
SERM – Selective estrogen receptor modulator 
RT – Radiotherapy 
NACT – Neoadjuvant chemotherapy 
DNA – Deoxy-ribonucleic acid 
EBRT – External Beam Radiotherapy 
HPE – Histopathological evaluation 
LHRH – Leutinising hormone releasing hormone 
FNAC – Fine needle aspiration cytology 
LD – Latissimus dorsi myocutaneous flap 
 
                                               Master Chart 
S.No Pt Age Menopausal Side  TNM   Stage Treatment 
1 L 54 Post  Rt T3N1M0 III A MRM +RT+ CT+ Tmx 
2 K 50 Pre  Lt T3N1M0 III A MRM + B/L  
Oopherectomy + RT + CT 
+ Tmx 
3. S 24 Pre Lt T4dN1M0 III B CT + B/L Oopherectomy + 
Tmx 
4 S 60 Post Lt T4bN2M0 III B MRM + CT + RT + Tmx 
5 M 52 Post Lt TxN1Mx IV Local excision + CT + 
Tmx 
6 V 50 Post Lt T3N2M0 III B MRM + CT + RT + Tmx 
7 G 41 Post 
oopherectomy 
Rt TxNxMx IV Local excision + CT + 
Tmx 
8 K 55 Pre Lt T3NoM0 II B  MRM + B/L  
Oopherectomy + RT + CT 
+ Tmx 
9 V 57 Post Rt T3N1M0 III A MRM + CT + RT + Tmx 
10. S 40 Post 
oopherectomy 
Rt TxNxM1 IV CT + Tmx 
11 M 56 Post Rt T4bN0M0 III B MRM + CT + RT + Tmx 
12 P 45 Post  Lt TxN0Mx IV CT + Tmx 
S.no Pt Age Menopausal Side TNM Stage Treatment 
13 N 35 Pre Lt T4cN2M1 IV CT + Tmx 
14 G 40 Pre Rt T3N1M1 IV CT + Tmx 
15 D 50 Pre Lt T2N1M0 II A  MRM + B/L  
Oopherectomy + RT + CT 
+ Tmx 
16 M 50 Post Lt T3N1M0 III A MRM + CT + RT + Tmx 
17 R 45 Pre Lt T2N1M0 II B MRM + B/L  
Oopherectomy + RT + CT 
+ Tmx 
18 V 42 Pre Rt T2NoMo II A MRM + B/L  
Oopherectomy + RT + CT 
+ Tmx 
19 M 55 Pre Rt T2N2M0 III A MRM + B/L  
Oopherectomy + RT + CT 
+ Tmx 
20 M 60 Post Lt T4bN3M1 IV CT + Tmx 
21 S 45 Pre Rt T3N1M0 III B MRM + B/L  
Oopherectomy + RT + CT 
+ Tmx 
22 M 60 Post Lt T4bN1M0 III A MRM + CT + RT + Tmx 
23 K 60 Post Rt T4bN1M0 III A SM + CT + RT + Tmx 
24 D 50 Post Rt T4bN1M0 III A MRM + CT + RT + Tmx 
S.No Pt Age Menopausal Side TNM Stage Treatment 
25 R 40 Pre Lt T3N1M0 III A MRM + B/L  
Oopherectomy + RT + CT 
+ Tmx 
26 J 50 Pre Rt T3N1M0 III A MRM + B/L  
Oopherectomy + RT + CT 
+ Tmx 
27 G 70 Post Rt T4bN1M0 III B MRM + CT + RT + Tmx 
28 K 55 Post Lt T3N1M0 III A MRM + CT + RT + Tmx 
29 J 55 Pre Rt TisN0Mo I MRM  
30 N 55 Pre Lt T4bN1M0 III B MRM + B/L  
Oopherectomy + RT + CT 
+ Tmx 
31 G 68 Post Rt T4bN1M0 III B MRM + CT + RT + Tmx 
32 J 65 Post Lt T3N1M0 III A MRM + CT + RT + Tmx 
33 L 40 Pre Lt T3N1M0 III A MRM + B/L  
Oopherectomy + RT + CT 
+ Tmx 
34 M 63 Post Rt T4bN1M0 III B MRM + CT + RT + Tmx 
35 P 70 Post Lt T4bN2M0 III B MRM + CT + RT + Tmx 
36 R 50 Pre Rt T4bN1M0 III B MRM + B/L  
Oopherectomy+ CT + RT 
+ Tmx 
37 S 45 Post Rt T4bN1M0 III B MRM + CT + RT + Tmx 
38 C 35 Pre Lt T4cN1M0 III B MRM + SSG +B/L  
Oopherectomy+ CT + RT 
+ Tmx 
39 K 61 Post Lt T4bN3M1 IV CT + Tmx 
40 M 51 Post Lt T4bN1M0 III B MRM + CT + RT + Tmx 
41 M 55 Post Rt T4bN1M0 III B MRM + CT + RT + Tmx 
42 G 50 Post Lt T4cN1M0 III B SM + CT + RT + Tmx 
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Figure : Carcinoma breast stage distribution in our study 
population. 
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ABBREVIATIONS USED 
LABC – Locally advanced breast carcinoma 
IBC – Inflammatory breast carcinoma 
MRM – Modified Radical Mastectomy 
SSM – Skin sparing mastectomy 
BCT – Breast conservation surgery 
NSSM – Non skin sparing mastectomy 
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SERM – Selective estrogen receptor modulator 
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HPE – Histopathological evaluation 
LHRH – Leutinising hormone releasing hormone 
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MASTER CHART 
S.No Pt Age Menopausal Side  TNM   Stage Treatment 
1 L 54 Post  Rt T3N1M0 III A MRM +RT+ CT+ Tmx 
2 K 50 Pre  Lt T3N1M0 III A MRM + B/L  
Oopherectomy + RT + CT 
+ Tmx 
3. S 24 Pre Lt T4dN1M0 III B CT + B/L Oopherectomy + 
Tmx 
4 S 60 Post Lt T4bN2M0 III B MRM + CT + RT + Tmx 
5 M 52 Post Lt TxN1Mx IV Local excision + CT + 
Tmx 
6 V 50 Post Lt T3N2M0 III B MRM + CT + RT + Tmx 
7 G 41 Post 
oopherectomy 
Rt TxNxMx IV Local excision + CT + 
Tmx 
8 K 55 Pre Lt T3NoM0 II B  MRM + B/L  
Oopherectomy + RT + CT 
+ Tmx 
9 V 57 Post Rt T3N1M0 III A MRM + CT + RT + Tmx 
10. S 40 Post 
oopherectomy 
Rt TxNxM1 IV CT + Tmx 
11 M 56 Post Rt T4bN0M0 III B MRM + CT + RT + Tmx 
12 P 45 Post  Lt TxN0Mx IV CT + Tmx 
S.no Pt Age Menopausal Side TNM Stage Treatment 
13 N 35 Pre Lt T4cN2M1 IV CT + Tmx 
14 G 40 Pre Rt T3N1M1 IV CT + Tmx 
15 D 50 Pre Lt T2N1M0 II A  MRM + B/L  
Oopherectomy + RT + CT 
+ Tmx 
16 M 50 Post Lt T3N1M0 III A MRM + CT + RT + Tmx 
17 R 45 Pre Lt T2N1M0 II B MRM + B/L  
Oopherectomy + RT + CT 
+ Tmx 
18 V 42 Pre Rt T2NoMo II A MRM + B/L  
Oopherectomy + RT + CT 
+ Tmx 
19 M 55 Pre Rt T2N2M0 III A MRM + B/L  
Oopherectomy + RT + CT 
+ Tmx 
20 M 60 Post Lt T4bN3M1 IV CT + Tmx 
21 S 45 Pre Rt T3N1M0 III B MRM + B/L  
Oopherectomy + RT + CT 
+ Tmx 
22 M 60 Post Lt T4bN1M0 III A MRM + CT + RT + Tmx 
23 K 60 Post Rt T4bN1M0 III A SM + CT + RT + Tmx 
24 D 50 Post Rt T4bN1M0 III A MRM + CT + RT + Tmx 
S.No Pt Age Menopausal Side TNM Stage Treatment 
25 R 40 Pre Lt T3N1M0 III A MRM + B/L  
Oopherectomy + RT + CT 
+ Tmx 
26 J 50 Pre Rt T3N1M0 III A MRM + B/L  
Oopherectomy + RT + CT 
+ Tmx 
27 G 70 Post Rt T4bN1M0 III B MRM + CT + RT + Tmx 
28 K 55 Post Lt T3N1M0 III A MRM + CT + RT + Tmx 
29 J 55 Pre Rt TisN0Mo I MRM  
30 N 55 Pre Lt T4bN1M0 III B MRM + B/L  
Oopherectomy + RT + CT 
+ Tmx 
31 G 68 Post Rt T4bN1M0 III B MRM + CT + RT + Tmx 
32 J 65 Post Lt T3N1M0 III A MRM + CT + RT + Tmx 
33 L 40 Pre Lt T3N1M0 III A MRM + B/L  
Oopherectomy + RT + CT 
+ Tmx 
34 M 63 Post Rt T4bN1M0 III B MRM + CT + RT + Tmx 
35 P 70 Post Lt T4bN2M0 III B MRM + CT + RT + Tmx 
36 R 50 Pre Rt T4bN1M0 III B MRM + B/L  
Oopherectomy+ CT + RT 
+ Tmx 
37 S 45 Post Rt T4bN1M0 III B MRM + CT + RT + Tmx 
38 C 35 Pre Lt T4cN1M0 III B MRM + SSG +B/L  
Oopherectomy+ CT + RT 
+ Tmx 
39 K 61 Post Lt T4bN3M1 IV CT + Tmx 
40 M 51 Post Lt T4bN1M0 III B MRM + CT + RT + Tmx 
41 M 55 Post Rt T4bN1M0 III B MRM + CT + RT + Tmx 
42 G 50 Post Lt T4cN1M0 III B SM + CT + RT + Tmx 
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